Loading... Please wait.
| Gene/Protein ⓘ |
Type | Normal/Tumor ⓘ |
HLA ⓘ |
HLA% ⓘ min |
|
Position ⓘ |
Lymphocyte Stimulation ⓘ |
Reference ⓘ |
Full Reference | Comment | Note ⓘ |
||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CDK12 | 0 | melanoma | A11 | 13 | CILGKLFTK | 924-932 | autologous tumor cells | Robbins, 2013 |
Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013 Jun, 19(6):747-52. doi: 10.1038/nm.3161. (PMID: 23644516) | ||||
| Cdc27 | 0 | melanoma | DR4 | 24 | FSWAMDLDPKGA | 760-771 | autologous tumor cells | Wang, 1999 |
Wang RF, Wang X, Atwood AC, Topalian SL, Rosenberg SA. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science. 1999 May 21, 284(5418):1351-4. (PMID: 10334988) | The mutation is not located in the region encoding the peptide | |||
| alpha-actinin-4 | 0 | lung carcinoma | A2 | 44 | FIASNGVKLV | 118-127 | autologous tumor cells | Echchakir, 2001 |
Echchakir H, Mami-Chouaib F, Vergnon I, Baurain JF, Karanikas V, Chouaib S, Coulie PG. A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res. 2001 May 15, 61(10):4078-83. (PMID: 11358829) | ||||
| CASP-8 | 0 | head and neck squamous cell carcinoma | B35 | 20 | FPSDSWCYF | 476-484 | autologous tumor cells | Mandruzzato, 1997 |
Mandruzzato S, Brasseur F, Andry G, Boon T, van der Bruggen P. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med. 1997 Aug 29, 186(5):785-93. (PMID: 9271594) | ||||
| CDKN2A | 0 | melanoma | A11 | 13 | AVCPWTWLR | 125-133 (p14ARF-ORF3) | autologous tumor cells | Huang, 2004 |
Huang J, El-Gamil M, Dudley ME, Li YF, Rosenberg SA, Robbins PF. T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. J Immunol. 2004 May 15, 172(10):6057-64. (PMID: 15128789) | ||||
| COA-1 | 0 | colorectal carcinoma | DR13 | 19 | TLYQDDTLTLQAAG | 447-460 | autologous tumor cells | Maccalli, 2003 |
Maccalli C, Li YF, El-Gamil M, Rosenberg SA, Robbins PF. Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes. Cancer Res. 2003 Oct 15, 63(20):6735-43. (PMID: 14583468) | The mutation is not located in the region encoding the peptide | |||
| CLPP | 0 | melanoma | A2 | 44 | ILDKVLVHL | 240-248 | autologous tumor cells | Corbière, 2011 |
Corbière V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethé B, van Baren N, Van den Eynde BJ, Boon T, Coulie PG. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res. 2011 Feb 15, 71(4):1253-62. (PMID: 21216894) | ||||
| COA-1 | 0 | colorectal carcinoma | DR4 | 24 | TLYQDDTLTLQAAG | 447-460 | autologous tumor cells | Maccalli, 2003 |
Maccalli C, Li YF, El-Gamil M, Rosenberg SA, Robbins PF. Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes. Cancer Res. 2003 Oct 15, 63(20):6735-43. (PMID: 14583468) | The mutation is not located in the region encoding the peptide | |||
| CSNK1A1 | 0 | melanoma | A2 | 44 | GLFGDIYLA | 26-34 | autologous tumor cells | Robbins, 2013 |
Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013 Jun, 19(6):747-52. (PMID: 23644516) | ||||
| EFTUD2 | 0 | melanoma | A3 | 22 | KILDAVVAQK | 668-677 | autologous tumor cells | Lennerz, 2005 |
Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C, Wölfel T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A. 2005 Nov 1, 102(44):16013-8. (PMID: 16247014) | ||||
| FN1 | 0 | melanoma | DR2 | 25 | MIFEKHGFRRTTPP | 2050-2063 | autologous tumor cells | Wang, 2002 |
Wang HY, Zhou J, Zhu K, Riker AI, Marincola FM, Wang RF. Identification of a mutated fibronectin as a tumor antigen recognized by CD4+ T cells: its role in extracellular matrix formation and tumor metastasis. J Exp Med. 2002 Jun 3, 195(11):1397-406. (PMID: 12045238) | ||||
| Elongation factor 2 | 0 | lung squamous CC | A68 | 8 | ETVSEQSNV | 581-589 | autologous tumor cells | Hogan, 1998 |
Hogan KT, Eisinger DP, Cupp SB 3rd, Lekstrom KJ, Deacon DD, Shabanowitz J, Hunt DF, Engelhard VH, Slingluff CL Jr, Ross MM. The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene. Cancer Res. 1998 Nov 15, 58(22):5144-50. (PMID: 9823325) | ||||
| GAS7 | 0 | melanoma | A2 | 44 | SLADEAEVYL | 141-150 | autologous tumor cells | Robbins, 2013 |
Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013 Jun, 19(6):747-52. (PMID: 23644516) | ||||
| PPP1R3B | 0 | melanoma | A1 | 26 | YTDFHCQYV | 172-180 | autologous tumor | Robbins, 2013 |
Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013 Jun, 19(6):747-52. (PMID: 23644516) | ||||
| CDK4 | 0 | melanoma | A2 | 44 | ACDPHSGHFV | 23-32 | autologous tumor cells | Wolfel, 1995 |
Wölfel T, Hauer M, Schneider J, Serrano M, Wölfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Büschenfelde KH, Beach D. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 1995 Sep 1, 269(5228):1281-4. (PMID: 7652577) | ||||
| ARTC1 | 0 | melanoma | DR1 | 18 | YSVYFNLPADTIYTN | autologous tumor cells | Wang, 2005 |
Wang HY, Peng G, Guo Z, Shevach EM, Wang RF. Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells. J Immunol. 2005 Mar 1, 174(5):2661-70. (PMID: 15728473) | The mutation creates a start codon (ATG) that opens an alternative ORF encoding the antigenic peptide. This peptide is recognized by regulatory T cells (Tregs) | ||||
| GPNMB | 0 | melanoma | A3 | 22 | TLDWLLQTPK | 179-188 | autologous tumor cells | Lennerz, 2005 |
Lennerz V1, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C, Wölfel T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A. 2005 Nov 1, 102(44):16013-8. (PMID: 16247014) | ||||
| beta-catenin | 0 | melanoma | A24 | 20 | SYLDSGIHF | 29-37 | autologous tumor cells | Robbins, 1996 |
Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, Rosenberg SA. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med. 1996 Mar 1, 183(3):1185-92. (PMID: 8642260) | ||||
| LDLR-fucosyltransferaseAS fusion protein | 0 | melanoma | DR1 | 18 | WRRAPAPGA | 315-323 | autologous tumor cells | Wang, 1999 |
Wang RF, Wang X, Rosenberg SA. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells. J Exp Med. 1999 May 17, 189(10):1659-68. (PMID: 10330445) | ||||
| HLA-A2 | 0 | renal cell carcinoma | autologous tumor cells | Brändle, 1996 |
Brändle D, Brasseur F, Weynants P, Boon T, Van den Eynde B. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J Exp Med. 1996 Jun 1, 183(6):2501-8. (PMID: 8676070) | The mutation affects the HLA itself | |||||||
| HAUS3 | 0 | melanoma | A2 | 44 | ILNAMIAKI | 154-162 | autologous tumor cells | Robbins, 2013 |
Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013 Jun, 19(6):747-52. (PMID: 23644516) | ||||
| hsp70-2 | 0 | renal cell carcinoma | A2 | 44 | SLFEGIDIYT | 286-295 | autologous tumor cells | Gaudin, 1999 |
Gaudin C, Kremer F, Angevin E, Scott V, Triebel F. A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma. J Immunol. 1999 Feb 1, 162(3):1730-8. | ||||
| MATN | 0 | melanoma | A11 | 13 | KTLTSVFQK | 226-234 | autologous tumor cells | Robbins, 2013 |
Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013 Jun, 19(6):747-52. (PMID: 23644516) | ||||
| ME1 | 0 | non-small cell lung carcinoma | A2 | 44 | FLDEFMEGV | 224-232 | autologous tumor cells | Karanikas, 2001 |
Karanikas V, Colau D, Baurain JF, Chiari R, Thonnard J, Gutierrez-Roelens I, Goffinet C, Van Schaftingen EV, Weynants P, Boon T, Coulie PG. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res. 2001 May 1, 61(9):3718-24. (PMID: 11325844) | ||||
| KIAAO205 | 0 | bladder tumor | B44 | 21 | AEPINIQTW | 262-270 | autologous tumor cells | Guéguen, 1998 |
Guéguen M, Patard JJ, Gaugler B, Brasseur F, Renauld JC, Van Cangh PJ, Boon T, Van den Eynde BJ. An antigen recognized by autologous CTLs on a human bladder carcinoma. J Immunol. 1998 Jun 15, 160(12):6188-94. (PMID: 9637538) | ||||
| MUM-1 | 0 | melanoma | B44 | 21 | EEKLIVVLF | 30-38 | autologous tumor cells | Coulie, 1995 |
Coulie PG, Lehmann F, Lethé B, Herman J, Lurquin C, Andrawiss M, Boon T. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A. 1995 Aug 15, 92(17):7976-80. (PMID: 7644523) | ||||
| MUM-2 | 0 | melanoma | B44 | 21 | SELFRSGLDSY | 123-133 | autologous tumor cells | Chiari, 1999 |
Chiari R, Foury F, De Plaen E, Baurain JF, Thonnard J, Coulie PG. Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene. Cancer Res. 1999 Nov 15, 59(22):5785-92. (PMID: 10582700) | ||||
| MUM-2 | 0 | melanoma | Cw6 | 18 | FRSGLDSYV | 126-134 | autologous tumor cells | Chiari, 1999 |
Chiari R, Foury F, De Plaen E, Baurain JF, Thonnard J, Coulie PG. Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene. Cancer Res. 1999 Nov 15, 59(22):5785-92. (PMID: 10582700) | ||||
| MUM-3 | 0 | melanoma | A68 | 8 | EAFIQPITR | 322-330 | autologous tumor cells | Baurain, 2000 |
Baurain JF, Colau D, van Baren N, Landry C, Martelange V, Vikkula M, Boon T, Coulie PG. High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene. J Immunol. 2000 Jun 1, 164(11):6057-66. (PMID: 10820291) | ||||
| LDLR-fucosyltransferaseAS fusion protein | 0 | melanoma | DR1 | 18 | PVTWRRAPA | 312-320 | autologous tumor cells | Wang, 1999 |
Wang RF, Wang X, Rosenberg SA. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells. J Exp Med. 1999 May 17, 189(10):1659-68. (PMID: 10330445) | ||||
| neo-PAP | 0 | melanoma | DR7 | 25 | RVIKNSIRLTL | 724-734 | autologous tumor cells | Topalian, 2002 |
Topalian SL, Gonzales MI, Ward Y, Wang X, Wang RF. Revelation of a cryptic major histocompatibility complex class II-restricted tumor epitope in a novel RNA-processing enzyme. Cancer Res. 2002 Oct 1, 62(19):5505-9. (PMID: 12359760) | The mutation is not located in the region encoding the peptide | |||
| MART2 | 0 | melanoma | A1 | 26 | FLEGNEVGKTY | 446-455 | autologous tumor cells | Kawakami, 2001 |
Kawakami Y, Wang X, Shofuda T, Sumimoto H, Tupesis J, Fitzgerald E, Rosenberg S. Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes. J Immunol. 2001 Feb 15, 166(4):2871-7. (PMID: 11160356) | ||||
| NFYC | 0 | lung squamous cell carcinoma | B52 | 5 | QQITKTEV | 275-282 | autologous tumor cells | Takenoyama, 2006 |
Takenoyama M, Baurain JF, Yasuda M, So T, Sugaya M, Hanagiri T, Sugio K, Yasumoto K, Boon T, Coulie PG. A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma. Int J Cancer. 2006 Apr 15, 118(8):1992-7. (PMID: 16287085) | ||||
| HLA-A11 | 0 | melanoma | autologous tumor cells | Huang, 2004 |
Huang J, El-Gamil M, Dudley ME, Li YF, Rosenberg SA, Robbins PF. T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. J Immunol. 2004 May 15, 172(10):6057-64. (PMID: 15128789) | The mutation affects the HLA itself | |||||||
| OS-9 | 0 | melanoma | B44 | 21 | KELEGILLL | 438-446 | autologous tumor cells | Vigneron, 2002 |
Vigneron N, Ooms A, Morel S, Degiovanni G, Van den Eynde B. Identification of a new peptide recognized by autologous cytolytic T lymphocytes on a human melanoma. 2002 January. | ||||
| PTPRK | 0 | melanoma | DR10 | 3 | PYYFAAELPPRNLPEP | 667-682 | autologous tumor cells | Novellino, 2003 |
Novellino L, Renkvist N, Rini F, Mazzocchi A, Rivoltini L, Greco A, Deho P, Squarcina P, Robbins PF, Parmiani G, Castelli C. Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen. J Immunol. 2003 Jun 15, 170(12):6363-70. (PMID: 12794170) | ||||
| HSDL1 | 0 | ovarian cancer | Cw14 | 4 | CYMEAVAL | 20-27 | autologous tumor cells | Wick, 2013 |
Wick DA, Webb JR, Nielsen JS, Martin SD, Kroeger DR, Milne K, Castellarin M, Twumasi-Boateng K, Watson PH, Holt RA, Nelson BH. Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. Clin Cancer Res. 2014 Mar 1, 20(5):1125-34. (PMID: 24323902) | ||||
| RBAF600 | 0 | melanoma | B7 | 17 | RPHVPESAF | 329-337 | autologous tumor cells | Lennerz, 2005 |
Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C, Wölfel T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A. 2005 Nov 1, 102(44):16013-8. (PMID: 16247014) | ||||
| N-ras | 0 | melanoma | A1 | 26 | ILDTAGREEY | 55-64 | autologous tumor cells | Linard, 2002 |
Linard B, Bézieau S, Benlalam H, Labarrière N, Guilloux Y, Diez E, Jotereau F. A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. J Immunol. 2002 May 1, 168(9):4802-8. (PMID: 11971032) | ||||
| SIRT2 | 0 | melanoma | A3 | 22 | KIFSEVTLK | 192-200 | autologous tumor cells | Lennerz, 2005 |
Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C, Wölfel T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A. 2005 Nov 1, 102(44):16013-8. (PMID: 16247014) | ||||
| SNRPD1 | 0 | melanoma | B38 | 5 | SHETVIIEL | 10-19 | autologous tumor cells | Lennerz, 2005 |
Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C, Wölfel T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A. 2005 Nov 1, 102(44):16013-8. (PMID: 16247014) | ||||
| Triosephosphate isomerase | 0 | melanoma | DR1 | 18 | GELIGILNAAKVPAD | 23-37 | autologous tumor cells | Pieper, 1999 |
Pieper R, Christian RE, Gonzales MI, Nishimura MI, Gupta G, Settlage RE, Shabanowitz J, Rosenberg SA, Hunt DF, Topalian SL. Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells. J Exp Med. 1999 Mar 1, 189(5):757-66. (PMID: 10049939) | ||||
| BCR-ABL fusion protein (b3a2) | 0 | chronic myeloid leukemia | B8 | 14 | GFKQSSKAL | 922-930 | peptide | Yotnda, 1998 |
Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP, Lemonnier FA, Leblond V, Langlade-Demoyen P. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest. 1998 May 15, 101(10):2290-6. (PMID: 9593785) | ||||
| Myosin class I | 0 | melanoma | A3 | 22 | KINKNPKYK | 911-919 | expansion of TIL with IL-2 | Zorn, 1999 |
Zorn E, Hercend T. A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. Eur J Immunol. 1999 Feb, 29(2):592-601. (PMID: 10064075) | ||||
| BCR-ABL fusion protein (b3a2) | 0 | chronic myeloid leukemia | DR4 | 24 | ATGFKQSSKALQRPVAS | 920-936 | peptide | Bosch, 1996 |
Bosch GJ, Joosten AM, Kessler JH, Melief CJ, Leeksma OC. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood. 1996 Nov 1, 88(9):3522-7. (PMID: 8896419) | ||||
| BCR-ABL fusion protein (b3a2) | 0 | chronic myeloid leukemia | A2 | 44 | SSKALQRPV | 926-934 | peptide | Yotnda, 1998 |
Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP, Lemonnier FA, Leblond V, Langlade-Demoyen P. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest. 1998 May 15, 101(10):2290-6. (PMID: 9593785) | ||||
| BCR-ABL fusion protein (b3a2) | 0 | chronic myeloid leukemia | DR9 | 3 | ATGFKQSSKALQRPVAS | 920-936 | peptide | Makita, 2002 |
Makita M, Azuma T, Hamaguchi H, Niiya H, Kojima K, Fujita S, Tanimoto M, Harada M, Yasukawa M. Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes. Leukemia. 2002 Dec, 16(12):2400-7. (PMID: 1245474) | ||||
| B-RAF | 0 | melanoma | DR4 | 24 | EDLTVKIGDFGLATEKSRWSGSHQFEQLS | 586-614 | peptide | Sharkey, 2004 |
Sharkey MS, Lizée G, Gonzales MI, Patel S, Topalian SL. CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation. Cancer Res. 2004 Mar 1, 64(5):1595-9. (PMID: 14996715) | ||||
| dek-can fusion protein | 0 | myeloid leukemia | DR53 | 49 | TMKQICKKEIRRLHQY | 342-357 | peptide | Makita, 2002 |
Makita M, Azuma T, Hamaguchi H, Niiya H, Kojima K, Fujita S, Tanimoto M, Harada M, Yasukawa M. Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes. Leukemia. 2002 Dec, 16(12):2400-7. (PMID: 12454745) | ||||
| ETV6-AML1 fusion protein | 0 | acute lymphoblastic leukemia | A2 | 44 | RIAECILGM | 334-342 | peptide | Yotnda, 1998 |
Yotnda P, Garcia F, Peuchmaur M, Grandchamp B, Duval M, Lemonnier F, Vilmer E, Langlade-Demoyen P. Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. J Clin Invest. 1998 Jul 15, 102(2):455-62. (PMID: 9664088) | ||||
| ETV6-AML1 fusion protein | 0 | acute lymphoblastic leukemia | DP5 | 3 | IGRIAECILGMNPSR | 332-346 | peptide | Yun, 1999 |
Yun C, Senju S, Fujita H, Tsuji Y, Irie A, Matsushita S, Nishimura Y. Augmentation of immune response by altered peptide ligands of the antigenic peptide in a human CD4+ T-cell clone reacting to TEL/AML1 fusion protein. Tissue Antigens. 1999 Aug, 54(2):153-61. (PMID: 10488742) | ||||
| CASP-5 | 0 | colorectal, gastric, and endometrial carcinoma | A2 | 44 | FLIIWQNTM | 67-75 | peptide | Schwitalle, 2004 |
Schwitalle Y, Linnebacher M, Ripberger E, Gebert J, von Knebel Doeberitz M. Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. 2004 January | Frameshift product | |||
| ETV6-AML1 fusion protein | 0 | acute lymphoblastic leukemia | DP17 | 1 | IGRIAECILGMNPSR | 332-346 | peptide | Yun, 1999 |
Yun C, Senju S, Fujita H, Tsuji Y, Irie A, Matsushita S, Nishimura Y. Augmentation of immune response by altered peptide ligands of the antigenic peptide in a human CD4+ T-cell clone reacting to TEL/AML1 fusion protein. Tissue Antigens. 1999 Aug, 54(2):153-61. (PMID: 10488742) | ||||
| FLT3-ITD | 0 | acute myelogenous leukemia | A1 | 26 | YVDFREYEYY | 591-600 | peptide | Graf, 2007 |
Graf C, Heidel F, Tenzer S, Radsak MP, Solem FK, Britten CM, Huber C, Fischer T, Wölfel T. A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells. Blood. 2007 Apr 1, 109(7):2985-8. (PMID: 17119119) | ||||
| OGT | 0 | colorectal carcinoma | A2 | 44 | SLYKFSPFPL | 28-37 | peptide | Ripberger, 2003 |
Ripberger E, Linnebacher M, Schwitalle Y, Gebert J, von Knebel Doeberitz M. Identification of an HLA-A0201-restricted CTL epitope generated by a tumor-specific frameshift mutation in a coding microsatellite of the OGT gene. J Clin Immunol. 2003 Sep, 23(5):415-23. (PMID: 14601650) | Frameshift product | |||
| FNDC3B | 0 | chronic lymphocytic leukemia | A2 | 44 | VVMSWAPPV | 292-300 | peptide | Rajasagi, 2004 |
Rajasagi M, Shukla SA, Fritsch EF, Keskin DB, DeLuca D, Carmona E, Zhang W, Sougnez C, Cibulskis K, Sidney J, Stevenson K, Ritz J, Neuberg D, Brusic V, Gabriel S, Lander ES, Getz G, Hacohen N, Wu CJ. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood. 2014 Jul 17, 124(3):453-62. (PMID: 24891321) | ||||
| p53 | 0 | head and neck squamous cell carcinoma | A2 | 44 | VVPCEPPEV | 217-225 | peptide | Ito, 2007 |
Ito D, Visus C, Hoffmann TK, Balz V, Bier H, Appella E, Whiteside TL, Ferris RL, DeLeo AB. Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck. Int J Cancer. 2007 Jun 15, 120(12):2618-24. (PMID: 17294448) | ||||
| pml-RARalpha fusion protein | 0 | promyelocytic leukemia | DR11 | 25 | NSNHVASGAGEAAIETQSSSSEEIV | peptide | Gambacorti, 1993 |
Gambacorti-Passerini C, Grignani F, Arienti F, Pandolfi PP, Pelicci PG, Parmiani G. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells. Blood. 1993 Mar 1, 81(5):1369-75. (PMID: 8095167) | |||||
| PRDX5 | 0 | melanoma | A2 | 44 | LLLDDLLVSI | 163-172 | peptide | Sensi, 2005 |
Sensi M, Nicolini G, Zanon M, Colombo C, Molla A, Bersani I, Lupetti R, Parmiani G, Anichini A. Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype. Cancer Res. 2005 Jan 15, 65(2):632-40. (PMID: 15695408) | ||||
| K-ras | 0 | pancreatic adenocarcinoma | B35 | 20 | VVVGAVGVG | 7-15 | peptide | Gjertsen, 1997 |
Gjertsen MK, Bjorheim J, Saeterdal I, Myklebust J, Gaudernack G. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer. 1997 Sep 4, 72(5):784-90. (PMID: 9311595) | ||||
| SYT-SSX1 or -SSX2 fusion protein | 0 | sarcoma | B7 | 17 | QRPYGYDQIM | 402-410 (SYT) | peptide | Worley, 2001 |
Worley BS, van den Broeke LT, Goletz TJ, Pendleton CD, Daschbach EM, Thomas EK, Marincola FM, Helman LJ, Berzofsky JA. Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res. 2001 Sep 15, 61(18):6868-75. (PMID: 11559563) | ||||
| TGF-betaRII | 0 | colorectal carcinoma | A2 | 44 | RLSSCVPVA | 131-139 | peptide | Linnebacher, 2001 |
Linnebacher M, Gebert J, Rudy W, Woerner S, Yuan YP, Bork P, von Knebel Doeberitz M. Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int J Cancer. 2001 Jul 1, 93(1):6-11. (PMID: 11391614) | Frameshift product | |||
| D393-CD20n | 1 | DR4 | 24 | KPLFRRMSSLELVIA | 28-42 | peptide | Vauchy, 2015 |
Vauchy C, Gamonet C, Ferrand C, Daguindau E, Galaine J, Beziaud L, Chauchet A, Henry Dunand CJ, Deschamps M, Rohrlich PS, Borg C, Adotevi O, Godet Y. CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopes. Int J Cancer. 2015 Jul 1, 137(1):116-26. (PMID: 25449106) | |||||
| KK-LC-1 | 1 | B15 | 13 | RQKRILVNL | 76-84 | autologous tumor cells | Fukuyama, 2006 |
Fukuyama T, Hanagiri T, Takenoyama M, Ichiki Y, Mizukami M, So T, Sugaya M, So T, Sugio K, Yasumoto K. Identification of a new cancer/germline gene, KK-LC-1, encoding an antigen recognized by autologous CTL induced on human lung adenocarcinoma. Cancer Res. 2006 May 1, 66(9):4922-8. (PMID: 16651449) | |||||
| HERV-K-MEL | 1 | A2 | 44 | MLAVISCAV | 1-9 | autologous tumor cells | Schiavetti, 2002 |
Schiavetti F1, Thonnard J, Colau D, Boon T, Coulie PG. A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. Cancer Res. 2002 Oct 1, 62(19):5510-6. (PMID: 12359761) | |||||
| BAGE-1 | 1 | Cw16 | 7 | AARAVFLAL | 2-10 | autologous tumor cells | Boel, 1995 |
Boël P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P, Boon T, van der Bruggen P. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity. 1995 Feb, 2(2):167-75. (PMID: 7895173) | |||||
| GAGE-1,2,8 | 1 | Cw6 | 18 | YRPRPRRY | 9-16 | autologous tumor cells | Van den Eynde, 1995 |
Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med. 1995 Sep 1, 182(3):689-98. | |||||
| GAGE-3,4,5,6,7 | 1 | A29 | 6 | YYWPRPRRY | 10-18 | autologous tumor cells | De Backer, 1999 |
De Backer O1, Arden KC, Boretti M, Vantomme V, De Smet C, Czekay S, Viars CS, De Plaen E, Brasseur F, Chomez P, Van den Eynde B, Boon T, van der Bruggen P. Characterization of the GAGE genes that are expressed in various human cancers and in normal testis. Cancer Res. 1999 Jul 1, 59(13):3157-65. (PMID: 10397259) | |||||
| MAGE-A9 | 1 | A2 | 44 | ALSVMGVYV | 223-231 | peptide | Oehlrich, 2005 |
Oehlrich N, Devitt G, Linnebacher M, Schwitalle Y, Grosskinski S, Stevanovic S, Zöller M. Generation of RAGE-1 and MAGE-9 peptide-specific cytotoxic T-lymphocyte lines for transfer in patients with renal cell carcinoma. Int J Cancer. 2005 Nov 1, 117(2):256-64. (PMID: 15900605) | |||||
| NA88-A | 1 | B13 | 6 | QGQHFLQKV | tumor-infiltrating lymphocytes | Moreau-Aubry, 2000 |
Moreau-Aubry A, Le Guiner S, Labarrière N, Gesnel MC, Jotereau F, Breathnach R. A processed pseudogene codes for a new antigen recognized by a CD8(+) T cell clone on melanoma. J Exp Med. 2000 May 1, 191(9):1617-24. (PMID: 10790436) | ||||||
| SSX-4 | 1 | DP10 | 2 | INKTSGPKRGKHAWTHRLRE | 151-170 | peptide | Ayyoub, 2005 |
Ayyoub M, Merlo A, Hesdorffer CS, Rimoldi D, Speiser D, Cerottini JC, Chen YT, Old LJ, Stevanovic S, Valmori D. CD4+ T cell responses to SSX-4 in melanoma patients. J Immunol. 2005 Apr 15, 174(8):5092-9. (PMID: 15814740) | |||||
| SSX-4 | 1 | DR3 | 21 | YFSKKEWEKMKSSEKIVYVY | 31-50 | peptide | Ayyoub, 2005 |
Ayyoub M, Merlo A, Hesdorffer CS, Rimoldi D, Speiser D, Cerottini JC, Chen YT, Old LJ, Stevanovic S, Valmori D. CD4+ T cell responses to SSX-4 in melanoma patients. J Immunol. 2005 Apr 15, 174(8):5092-9. (PMID: 15814740) | |||||
| SSX-4 | 1 | DR8 | 4 | KHAWTHRLRERKQLVVYEEI | 161-180 | peptide | Valmori, 2006 |
Valmori D, Qian F, Ayyoub M, Renner C, Merlo A, Gnjatic S, Stockert E, Driscoll D, Lele S, Old LJ, Odunsi K. Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells. Clin Cancer Res. 2006 Jan 15, 12(2):398-404. (PMID: 16428478) | |||||
| SSX-4 | 1 | DR8 | 4 | MKLNYEVMTKLGFKVTLPPF | 51-70 | peptide | Valmori, 2006 |
Valmori D, Qian F, Ayyoub M, Renner C, Merlo A, Gnjatic S, Stockert E, Driscoll D, Lele S, Old LJ, Odunsi K. Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells. Clin Cancer Res. 2006 Jan 15, 12(2):398-404. (PMID: 16428478) | |||||
| SSX-4 | 1 | DR15 | 20 | KSSEKIVYVYMKLNYEVMTK | 41-60 | peptide | Ayyoub, 2005 |
Ayyoub M, Merlo A, Hesdorffer CS, Rimoldi D, Speiser D, Cerottini JC, Chen YT, Old LJ, Stevanovic S, Valmori D. CD4+ T cell responses to SSX-4 in melanoma patients. J Immunol. 2005 Apr 15, 174(8):5092-9. (PMID: 15814740) | |||||
| TAG-1 | 1 | A2 | 44 | SLGWLFLLL | 78-86 | peptide | Adair, 2008 |
Adair SJ, Carr TM, Fink MJ, Slingluff CL Jr, Hogan KT. The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes. J Immunother. 2008 Jan, 31(1):7-17. (PMID: 18157007) | |||||
| SSX-4 | 1 | DR11 | 25 | LGFKVTLPPFMRSKRAADFH | 61-80 | peptide | Ayyoub, 2005 |
Ayyoub M, Merlo A, Hesdorffer CS, Rimoldi D, Speiser D, Cerottini JC, Chen YT, Old LJ, Stevanovic S, Valmori D. CD4+ T cell responses to SSX-4 in melanoma patients. J Immunol. 2005 Apr 15, 174(8):5092-9. (PMID: 15814740) | |||||
| TRAG-3 | 1 | DR1 | 18 | CEFHACWPAFTVLGE | 34-48 | peptide | Janjic, 2006 |
Janjic B, Andrade P, Wang XF, Fourcade J, Almunia C, Kudela P, Brufsky A, Jacobs S, Friedland D, Stoller R, Gillet D, Herberman RB, Kirkwood JM, Maillere B, Zarour HM. Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers. J Immunol. 2006 Aug 15, 177(4):2717-27. (PMID: 16888034) | |||||
| TAG-1 | 1 | B8 | 14 | LSRLSNRLL | 42-50 | peptide | Adair, 2008 |
Adair SJ, Carr TM, Fink MJ, Slingluff CL Jr, Hogan KT. The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes. J Immunother. 2008 Jan, 31(1):7-17. (PMID: 18157007) | |||||
| TAG-2 | 1 | B8 | 14 | LSRLSNRLL | 42-50 | peptide | Adair, 2008 |
Adair SJ, Carr TM, Fink MJ, Slingluff CL Jr, Hogan KT. The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes. J Immunother. 2008 Jan, 31(1):7-17. (PMID: 18157007) | |||||
| SSX-4 | 1 | DR52 | 41 | KHAWTHRLRERKQLVVYEEI | 161-180 | peptide | Valmori, 2006 |
Valmori D, Qian F, Ayyoub M, Renner C, Merlo A, Gnjatic S, Stockert E, Driscoll D, Lele S, Old LJ, Odunsi K. Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells. Clin Cancer Res. 2006 Jan 15, 12(2):398-404. (PMID: 16428478) | |||||
| TRAG-3 | 1 | DR4 | 24 | CEFHACWPAFTVLGE | 34-48 | peptide | Janjic, 2006 |
Janjic B, Andrade P, Wang XF, Fourcade J, Almunia C, Kudela P, Brufsky A, Jacobs S, Friedland D, Stoller R, Gillet D, Herberman RB, Kirkwood JM, Maillere B, Zarour HM. Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers. J Immunol. 2006 Aug 15, 177(4):2717-27. (PMID: 16888034) | |||||
| TRAG-3 | 1 | DR7 | 25 | CEFHACWPAFTVLGE | 34-48 | peptide | Janjic, 2006 |
Janjic B, Andrade P, Wang XF, Fourcade J, Almunia C, Kudela P, Brufsky A, Jacobs S, Friedland D, Stoller R, Gillet D, Herberman RB, Kirkwood JM, Maillere B, Zarour HM. Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers. J Immunol. 2006 Aug 15, 177(4):2717-27. (PMID: 16888034) | |||||
| XAGE-1b/GAGED2a | 1 | A2 | 44 | RQKKIRIQL | 21-29 | peptide | Ohue, 2012 |
Ohue Y, Eikawa S, Okazaki N, Mizote Y, Isobe M, Uenaka A, Fukuda M, Old LJ, Oka M, Nakayama E. Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients. Int J Cancer. 2012 Sep 1, 131(5):E649-58. (PMID: 22109656) | |||||
| XAGE-1b/GAGED2a | 1 | DR4 | 24 | HLGSRQKKIRIQLRSQ | 17-32 | peptide | Ohue, 2012 |
Ohue Y, Eikawa S, Okazaki N, Mizote Y, Isobe M, Uenaka A, Fukuda M, Old LJ, Oka M, Nakayama E. Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients. Int J Cancer. 2012 Sep 1, 131(5):E649-58. (PMID: 22109656) | |||||
| XAGE-1b/GAGED2a | 1 | DR9 | 3 | CATWKVICKSCISQTPG | 33-49 | autologous tumor cells | Shimono, 2007 |
Shimono M, Uenaka A, Noguchi Y, Sato S, Okumura H, Nakagawa K, Kiura K, Tanimoto M, Nakayama E. Identification of DR9-restricted XAGE antigen on lung adenocarcinoma recognized by autologous CD4 T-cells. Int J Oncol. 2007 Apr, 30(4):835-40. (PMID: 17332921) | |||||
| gp100 / Pmel17 | 2 | melanoma | A2 | 44 | KTWGQYWQV | 154-162 | autologous tumor cells | Bakker, 1995 |
Bakker AB, Schreurs MW, Tafazzul G, de Boer AJ, Kawakami Y, Adema GJ, Figdor CG. Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. Int J Cancer. 1995 Jul 4, 62(1):97-102. (PMID: 7541395) | ||||
| gp100 / Pmel17 | 2 | melanoma | A2 | 44 | (A)MLGTHTMEV | 177(8)-186 | peptide | Tsai, 1997 |
Tsai V, Southwood S, Sidney J, Sakaguchi K, Kawakami Y, Appella E, Sette A, Celis E. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J Immunol. 1997 Feb 15, 158(4):1796-802. (PMID: 9029118) | ||||
| gp100 / Pmel17 | 2 | melanoma | A2 | 44 | KTWGQYWQV | 154-163 | autologous tumor cells | Kawakami, 1995 |
Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol. 1995 Apr 15, 154(8):3961-8. (PMID: 7706734) | ||||
| gp100 / Pmel17 | 2 | melanoma | A2 | 44 | ITDQVPFSV | 209-217 | autologous tumor cells | Kawakami, 1995 |
Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol. 1995 Apr 15, 154(8):3961-8. (PMID: 7706734) | ||||
| gp100 / Pmel17 | 2 | melanoma | A2 | 44 | YLEPGPVTA | 280-288 | autologous tumor cells | Cox, 1994 |
Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL Jr. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science. 1994 Apr 29, 264(5159):716-9. (PMID: 7513441) | ||||
| gp100 / Pmel17 | 2 | melanoma | A2 | 44 | VLYRYGSFSV | 476-485 | autologous tumor cells | Kawakami, 1995 |
Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol. 1995 Apr 15, 154(8):3961-8. (PMID: 7706734) | ||||
| gp100 / Pmel17 | 2 | melanoma | A2 | 44 | LLDGTATLRL | 457-466 | autologous tumor cells | Kawakami, 1994 |
Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A. 1994 Jul 5, 91(14):6458-62. (PMID: 8022805) | ||||
| gp100 / Pmel17 | 2 | melanoma | A2 | 44 | RLMKQDFSV | 619-627 | autologous tumor cells | Kawakami, 1998 |
Kawakami Y, Robbins PF, Wang X, Tupesis JP, Parkhurst MR, Kang X, Sakaguchi K, Appella E, Rosenberg SA. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J Immunol. 1998 Dec 15, 161(12):6985-92. (PMID: 9862734) | ||||
| gp100 / Pmel17 | 2 | melanoma | A2 | 44 | SLADTNSLAV | 570-579 | peptide | Tsai, 1997 |
Tsai V, Southwood S, Sidney J, Sakaguchi K, Kawakami Y, Appella E, Sette A, Celis E. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J Immunol. 1997 Feb 15, 158(4):1796-802. (PMID: 9029118) | ||||
| gp100 / Pmel17 | 2 | melanoma | A3 | 22 | LIYRRRLMK | 614-622 | autologous tumor cells | Kawakami, 1998 |
Kawakami Y, Robbins PF, Wang X, Tupesis JP, Parkhurst MR, Kang X, Sakaguchi K, Appella E, Rosenberg SA. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J Immunol. 1998 Dec 15, 161(12):6985-92. (PMID: 9862734) | ||||
| gp100 / Pmel17 | 2 | melanoma | A2 | 44 | RLPRIFCSC | 639-647 | autologous tumor cells | Kawakami, 1998 |
Kawakami Y, Robbins PF, Wang X, Tupesis JP, Parkhurst MR, Kang X, Sakaguchi K, Appella E, Rosenberg SA. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J Immunol. 1998 Dec 15, 161(12):6985-92. (PMID: 9862734) | ||||
| gp100 / Pmel17 | 2 | melanoma | A3 | 22 | IALNFPGSQK | 86-95 | peptide | Kawashima, 1998 |
Kawashima I, Tsai V, Southwood S, Takesako K, Celis E, Sette A. Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells. Int J Cancer. 1998 Nov 9, 78(4):518-24. (PMID: 9797143) | ||||
| gp100 / Pmel17 | 2 | melanoma | A3 | 22 | ALLAVGATK | 17-25 | autologous tumor cells | Skipper, 1996 |
Skipper JC, Kittlesen DJ, Hendrickson RC, Deacon DD, Harthun NL, Wagner SN, Hunt DF, Engelhard VH, Slingluff CL Jr. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. J Immunol. 1996 Dec 1, 157(11):5027-33. (PMID: 8943411) | ||||
| gp100 / Pmel17 | 2 | melanoma | A3 | 22 | RSYVPLAHR | 195-202 and 191 or 192e | autologous tumor cells | Michaux, 2014 |
Michaux A, Larrieu P, Stroobant V, Fonteneau JF, Jotereau F, Van den Eynde BJ, Moreau-Aubry A, Vigneron N. A spliced antigenic peptide comprising a single spliced amino acid is produced in the proteasome by reverse splicing of a longer peptide fragment followed by trimming. J Immunol. 2014 Feb 15, 192(4):1962-71. (PMID: 24453253) | ||||
| gp100 / Pmel17 | 2 | melanoma | A3 | 22 | ALNFPGSQK | 87-95 | peptide | Kawashima, 1998 |
Kawashima I, Tsai V, Southwood S, Takesako K, Celis E, Sette A. Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells. Int J Cancer. 1998 Nov 9, 78(4):518-24. (PMID: 9797143) | ||||
| gp100 / Pmel17 | 2 | melanoma | A24 | 20 | VYFFLPDHL | intron 4 | autologous tumor cells | Robbins, 1997 |
Robbins PF, El-Gamil M, Li YF, Fitzgerald EB, Kawakami Y, Rosenberg SA. The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. J Immunol. 1997 Jul 1, 159(1):303-8. (PMID: 9200467) | ||||
| gp100 / Pmel17 | 2 | melanoma | A11 | 13 | ALNFPGSQK | 87-95 | peptide | Kawashima, 1998 |
Kawashima I, Tsai V, Southwood S, Takesako K, Celis E, Sette A. Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells. Int J Cancer. 1998 Nov 9, 78(4):518-24. (PMID: 9797143) | ||||
| gp100 / Pmel17 | 2 | melanoma | B7 | 17 | SSPGCQPPA | 529-537 | autologous tumor cells | Lennerz, 2005 |
Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C, Wölfel T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A. 2005 Nov 1, 102(44):16013-8. (PMID: 16247014) | ||||
| gp100 / Pmel17 | 2 | melanoma | A68 | 8 | HTMEVTVYHR | 182-191 | autologous tumor cells | Sensi, 2002 |
Sensi M, Pellegatta S, Vegetti C, Nicolini G, Parmiani G, Anichini A. Identification of a novel gp100/pMel17 peptide presented by HLA-A*6801 and recognized on human melanoma by cytolytic T cell clones. Tissue Antigens. 2002 Apr, 59(4):273-9. (PMID: 12135425) | ||||
| gp100 / Pmel17 | 2 | melanoma | A32 | 8 | RTKQLYPEW | 40-42 and 47-52 | autologous tumor cells | Vigneron, 2004 |
Vigneron N, Stroobant V, Chapiro J, Ooms A, Degiovanni G, Morel S, van der Bruggen P, Boon T, Van den Eynde BJ. An antigenic peptide produced by peptide splicing in the proteasome. Science. 2004 Apr 23, 304(5670):587-90. (PMID: 15001714) | ||||
| gp100 / Pmel17 | 2 | melanoma | B35 | 20 | VPLDCVLYRY | 471-480 | autologous tumor cells | Benlalam, 2003 |
Benlalam H, Linard B, Guilloux Y, Moreau-Aubry A, Derré L, Diez E, Dreno B, Jotereau F, Labarrière N. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes. J Immunol. 2003 Dec 1, 171(11):6283-9. (PMID: 14634146) | ||||
| gp100 / Pmel17 | 2 | melanoma | DQ6 | 63 | GRAMLGTHTMEVTVY | 175-189 | peptide | Kobayashi, 2001 |
Kobayashi H, Lu J, Celis E. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen. Cancer Res. 2001 Oct 15, 61(20):7577-84. (PMID: 11606397) | ||||
| gp100 / Pmel17 | 2 | melanoma | DR4 | 24 | WNRQLYPEWTEAQRLD | 44-59 | peptide | Touloukian, 2000 |
Touloukian CE, Leitner WW, Topalian SL, Li YF, Robbins PF, Rosenberg SA, Restifo NP. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. J Immunol. 2000 Apr 1, 164(7):3535-42. (PMID: 10725708) | ||||
| gp100 / Pmel17 | 2 | melanoma | B35 | 20 | LPHSSSHWL | 630-638 | autologous tumor cells | Vigneron, 2005 |
Vigneron N, Ooms A, Morel S, Ma W, Degiovanni G, Van den Eynde BJ. A peptide derived from melanocytic protein gp100 and presented by HLA-B35 is recognized by autologous cytolytic T lymphocytes on melanoma cells. Tissue Antigens. 2005 Feb, 65(2):156-62. (PMID: 15713214) | ||||
| gp100 / Pmel17 | 2 | melanoma | DR7 | 25 | TTEWVETTARELPIPEPE | 420-437 | protein | Parkhurst, 2004 |
Parkhurst MR, Riley JP, Robbins PF, Rosenberg SA. Induction of CD4+ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein. J Immunother. 2004 Mar-Apr, 27(2):79-91. (PMID: 14770079) | ||||
| gp100 / Pmel17 | 2 | melanoma | DR7 | 25 | TGRAMLGTHTMEVTVYH | 174-190 | retrovirus - dendritic cells | Lapointe, 2001 |
Lapointe R, Royal RE, Reeves ME, Altomare I, Robbins PF, Hwu P. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100. J Immunol. 2001 Oct 15, 167(8):4758-64. (PMID: 11591807) | ||||
| gp100 / Pmel17 | 2 | melanoma | DR53 | 49 | GRAMLGTHTMEVTVY | 175-189 | peptide | Kobayashi, 2001 |
Kobayashi H, Lu J, Celis E. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen. Cancer Res. 2001 Oct 15, 61(20):7577-84. (PMID: 11606397) | ||||
| gp100 / Pmel17 | 2 | melanoma | Cw8 | 7 | SNDGPTLI | 71-78 | autologous tumor cells | Castelli, 1999 |
Castelli C, Tarsini P, Mazzocchi A, Rini F, Rivoltini L, Ravagnani F, Gallino F, Belli F, Parmiani G. Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens. J Immunol. 1999 Feb 1, 162(3):1739-48. (PMID: 9973437) | ||||
| AIM-2 | 3 | ubiquitous (low level) | A1 | 26 | RSDSGQQARY | intron | autologous tumor cells | Harada, 2001 |
Harada M, Li YF, El-Gamil M, Ohnmacht GA, Rosenberg SA, Robbins PF. Melanoma-Reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types. J Immunother. 2001 Jul-Aug, 24(4):323-33. (PMID: 11565834) | ||||
| Meloe | 3 | ubiquitous (low level) | A2 | 44 | TLNDECWPA | 36-44 | tumor-infiltrating lymphocytes | Godet, 2008 |
Godet Y, Moreau-Aubry A, Guilloux Y, Vignard V, Khammari A, Dreno B, Jotereau F, Labarriere N. MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency. J Exp Med. 2008 Oct 27, 205(11):2673-82. (PMID: 18936238) | ||||
| Meloe | 3 | ubiquitous (low level) | DQ2 | 41 | ERISSTLNDECWPA | 31-44 | peptide/protein | Bobinet, 2012 |
Bobinet M, Vignard V, Rogel A, Khammari A, Dreno B, Lang F, Labarriere N. MELOE-1 antigen contains multiple HLA class II T cell epitopes recognized by Th1 CD4+ T cells from melanoma patients. PLoS One. 2012, 7(12):e51716. (PMID: 23284752) | ||||
| Meloe | 3 | ubiquitous (low level) | DQ6 | 63 | FGRLQGISPKI | 32-44 | peptide | Rogel, 2011 |
Rogel A, Vignard V, Bobinet M, Labarriere N, Lang F. A long peptide from MELOE-1 contains multiple HLA class II T cell epitopes in addition to the HLA-A*0201 epitope: an attractive candidate for melanoma vaccination. Cancer Immunol Immunother. 2011 Mar, 60(3):327-37. (PMID: 21080167) | ||||
| Meloe | 3 | ubiquitous (low level) | DR1 | 18 | TSREQFLPSEGAA | 11-23 | peptide/protein | Bobinet, 2012 |
Bobinet M, Vignard V, Rogel A, Khammari A, Dreno B, Lang F, Labarriere N. MELOE-1 antigen contains multiple HLA class II T cell epitopes recognized by Th1 CD4+ T cells from melanoma patients. PLoS One. 2012, 7(12):e51716. (PMID: 23284752) | ||||
| Meloe | 3 | ubiquitous (low level) | DR11 | 25 | CPPWHPSERISSTL | 24-37 | peptide | Rogel, 2011 |
Rogel A, Vignard V, Bobinet M, Labarriere N, Lang F. A long peptide from MELOE-1 contains multiple HLA class II T cell epitopes in addition to the HLA-A*0201 epitope: an attractive candidate for melanoma vaccination. Cancer Immunol Immunother. 2011 Mar, 60(3):327-37. (PMID: 21080167) | ||||
| MUC5AC | 3 | surface mucosal cells, respiratory tract, and stomach epithelia | A24 | 20 | TCQPTCRSL | 716-724 | peptide | Yamazoe, 2011 |
Yamazoe S, Tanaka H, Iwauchi T, Yoshii M, Ito G, Amano R, Yamada N, Sawada T, Ohira M, Hirakawa K. Identification of HLA-A*0201- and A*2402-restricted epitopes of mucin 5AC expressed in advanced pancreatic cancer. Pancreas. 2011 Aug, 40(6):896-904. (PMID: 21697763) | ||||
| RAGE-1 | 3 | retina | A2 | 44 | LKLSGVVRL | 352-360 | peptide | Oehlrich, 2005 |
Oehlrich N, Devitt G, Linnebacher M, Schwitalle Y, Grosskinski S, Stevanovic S, Zöller M. Generation of RAGE-1 and MAGE-9 peptide-specific cytotoxic T-lymphocyte lines for transfer in patients with renal cell carcinoma. Int J Cancer. 2005 Nov 1, 117(2):256-64. (PMID: 15900605) | ||||
| RAGE-1 | 3 | retina | A2 | 44 | PLPPARNGGLg | 32-40 | peptide | Oehlrich, 2005 |
Oehlrich N, Devitt G, Linnebacher M, Schwitalle Y, Grosskinski S, Stevanovic S, Zöller M. Generation of RAGE-1 and MAGE-9 peptide-specific cytotoxic T-lymphocyte lines for transfer in patients with renal cell carcinoma. Int J Cancer. 2005 Nov 1, 117(2):256-64. (PMID: 15900605) | ||||
| RAGE-1 | 3 | retina | B7 | 17 | SPSSNRIRNT | 11-20 | autologous tumor cells | Gaugler, 1996 |
Gaugler B, Brouwenstijn N, Vantomme V, Szikora JP, Van der Spek CW, Patard JJ, Boon T, Schrier P, Van den Eynde BJ. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenetics. 1996, 44(5):323-30. (PMID: 8781117) | ||||
| RNF43 | 3 | A2 | 44 | ALWPWLLMA(T) | 11-19(20) | peptide | Uchida, 2004 |
Uchida N, Tsunoda T, Wada S, Furukawa Y, Nakamura Y, Tahara H. Ring finger protein 43 as a new target for cancer immunotherapy. Clin Cancer Res. 2004 Dec 15, 10(24):8577-86. (PMID: 15623641) | |||||
| RNF43 | 3 | A24 | 20 | NSQPVWLCL | 721-729 | peptide | Uchida, 2004 |
Uchida N, Tsunoda T, Wada S, Furukawa Y, Nakamura Y, Tahara H. Ring finger protein 43 as a new target for cancer immunotherapy. Clin Cancer Res. 2004 Dec 15, 10(24):8577-86. (PMID: 15623641) | |||||
| K-ras | 0 | metastatic colorectal cancer | Cw8 | 7 | GADGVGKSA | 10-18 | autologous tumor cells | Tran, 2016 |
Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, Kriley IR, Rosenberg SA. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med. 2016; 375(23): 2255-2262. (PMID: 27959684) | ||||
| K-ras | 0 | metastatic colorectal cancer | Cw8 | 7 | GADGVGKSAL | 10-19 | autologous tumor cells | Tran, 2016 |
Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, Kriley IR, Rosenberg SA. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med. 2016; 375(23): 2255-2262. (PMID: 27959684) | ||||
| TP53 | 0 | A2 | 44 | VVPCEPPEV | 217-225 | expansion of TIL | Malekzadeh, 2019 |
Malekzadeh P, Pasetto A, Robbins PF, Parkhurst MR, Paria BC, Jia L, Gartner JJ, Hill V, Yu Z, Restifo NP, Sachs A, Tran E, Lo W, Somerville RP, Rosenberg SA, Deniger DC. Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. J Clin Invest. 2019 Mar 1, 129(3):1109-1114. (PMID: 30714987) | |||||
| HERV-E | 1 | A11 | 13 | ATFLGSLTWK | autologous tumor cells | Takahashi, 2008 |
Takahashi Y, Harashima N, Kajigaya S, Yokoyama H, Cherkasova E, McCoy JP, Hanada K-i, Mena O, Kurlander R, Abdul T, Srinivasan R, Lundqvist A, Malinzak E, Geller N, Lerman MI, Childs RW. Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J Clin Invest. 2008 Mar 3, 118(3):1099–1109. (PMID: 18292810) | ||||||
| HSPH1 | 3 | ubiquitous (low level) | A24 | 20 | NYGIYKQDL | 180-188 | peptide | Shimizu, 2019 |
Shimizu Y, Yoshikawa T, Kojima T, Shoda K, Nosaka K, Mizuno S, Wada S, Fujimoto Y, Sasada T, Kohashi K, Bando H, Endo I, Nakatsura T. Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial. Cancer Sci 2019, 110: 3049-3060. (PMID: 31390678) | ||||
| HSPH1 | 3 | ubiquitous (low level) | A2 | 44 | RLMNDMTAV | 169-177 | peptide | Shimizu, 2019 |
Shimizu Y, Yoshikawa T, Kojima T, Shoda K, Nosaka K, Mizuno S, Wada S, Fujimoto Y, Sasada T, Kohashi K, Bando H, Endo I, Nakatsura T. Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial. Cancer Sci 2019, 110: 3049-3060. (PMID: 31390678) | ||||
AP2S1
|
0 | Colorectal cancer | A24 | 20 | AYLEAIHKF | 79-87 | peptide | Shinkawa, 2021 |
Shinkawa T, Tokita S, Nakatsugawa M, Kikuchi Y, Kanaseki T, Torigoe T. Characterization of CD8+ T-cell responses to non-anchor-type HLA class I neoantigens with single amino-acid substitutions. Oncoimmunology. 2021 10(1):1870062. (PMID: 33537174) | ||||
| Cyclin-A1 | 1 |
|
A2 | 44 | SLIAAAAFCLA | 341-351 | peptide | Ochsenreither, 2012 |
Ochsenreither S, Majeti R, Schmitt T, Stirewalt D, Keilholz U, Loeb KR, Wood B, Choi YE, Bleakley M, Warren EH, Hudecek M, Akatsuka Y, Weissman IL, Greenberg PD. Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. Blood. 2012 Jun 7, 119(23):5492-501. (PMID: 22529286) | ||||
| Cyclin-A1 | 1 |
|
A2 | 44 | FLDRFLSCM | 227-235 | peptide | Ochsenreither, 2012 |
Ochsenreither S, Majeti R, Schmitt T, Stirewalt D, Keilholz U, Loeb KR, Wood B, Choi YE, Bleakley M, Warren EH, Hudecek M, Akatsuka Y, Weissman IL, Greenberg PD. Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. Blood. 2012 Jun 7, 119(23):5492-501. (PMID: 22529286) | ||||
| KM-HN-1 | 1 |
|
A24 | 20 | NYNNFYRFL | 196-204 | peptide | Monji, 2004 |
Monji M, Nakatsura T, Senju S, Yoshitake Y, Sawatsubashi M, Shinohara M, Kageshita T, Ono T, Inokuchi A, Nishimura Y. Identification of a novel human cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses. Clin Cancer Res. 2004 Sep 15, 10(18 Pt 1):6047-57. (PMID: 15447989) | ||||
| KM-HN-1 | 1 |
|
A24 | 20 | EYSKECLKEF | 499-508 | peptide | Monji, 2004 |
Monji M, Nakatsura T, Senju S, Yoshitake Y, Sawatsubashi M, Shinohara M, Kageshita T, Ono T, Inokuchi A, Nishimura Y. Identification of a novel human cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses. Clin Cancer Res. 2004 Sep 15, 10(18 Pt 1):6047-57. (PMID: 15447989) | ||||
| LAGE-1 | 1 |
|
A2 | 44 | MLMAQEALAFL | ORF2 | autologous tumor cells | Aarnoudse, 1999 |
Aarnoudse CA, van den Doel PB, Heemskerk B, Schrier PI. Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. Int J Cancer. 1999 Jul 30, 82(3):442-8. (PMID: 10399963) | ||||
| KM-HN-1 | 1 |
|
A24 | 20 | EYLSLSDKI | 770-778 | peptide | Monji, 2004 |
Monji M, Nakatsura T, Senju S, Yoshitake Y, Sawatsubashi M, Shinohara M, Kageshita T, Ono T, Inokuchi A, Nishimura Y. Identification of a novel human cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses. Clin Cancer Res. 2004 Sep 15, 10(18 Pt 1):6047-57. (PMID: 15447989) | ||||
| LAGE-1 | 1 |
|
A2 | 44 | MLMAQEALAFL | (1-11) | autologous tumor cells | Aarnoudse, 1999 |
Aarnoudse CA, van den Doel PB, Heemskerk B, Schrier PI. Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. Int J Cancer. 1999 Jul 30, 82(3):442-8. (PMID: 10399963) | ||||
| LAGE-1 | 1 |
|
A2 | 44 | SLLMWITQC | 157-165 | peptide | Rimoldi, 2000 |
Rimoldi D, Rubio-Godoy V, Dutoit V, Lienard D, Salvi S, Guillaume P, Speiser D, Stockert E, Spagnoli G, Servis C, Cerottini JC, Lejeune F, Romero P, Valmori D. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma. J Immunol. 2000 Dec 15, 165(12):7253-61. (PMID: 11120859) | ||||
| LAGE-1 | 1 |
|
A31 | 5 | LAAQERRVPR | ORF2 | autologous tumor cells | Wang, 1998 |
Wang RF, Johnston SL, Zeng G, Topalian SL, Schwartzentruber DJ, Rosenberg SA. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol. 1998 Oct 1, 161(7):3598-606. (PMID: 9759882) | ||||
| LAGE-1 | 1 |
|
A31 | 5 | LAAQERRVPR | (18-27) | autologous tumor cells | Wang, 1998 |
Wang RF, Johnston SL, Zeng G, Topalian SL, Schwartzentruber DJ, Rosenberg SA. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol. 1998 Oct 1, 161(7):3598-606. (PMID: 9759882) | ||||
| LAGE-1 | 1 |
|
B7 | 17 | APRGVRMAV | ORF2 | adenovirus-APC | Slager, 2004 |
Slager EH, van der Minne CE, Goudsmit J, van Oers JM, Kostense S, Havenga MJ, Osanto S, Griffioen M. Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber. Cancer Gene Ther. 2004 Mar, 11(3):227-36. (PMID: 14726960) | ||||
| LAGE-1 | 1 |
|
A68 | 8 | ELVRRILSR | 103-111 | adenovirus-dendritic cells | Sun, 2006 |
Sun Z, Lethé B, Zhang Y, Russo V, Colau D, Stroobant V, Boon T, van der Bruggen P. A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors. Cancer Immunol Immunother. 2006 Jun, 55(6):644-52. (PMID: 16187088) | ||||
| LAGE-1 | 1 |
|
B7 | 17 | APRGVRMAV | ( 46-54) | adenovirus-APC | Slager, 2004 |
Slager EH, van der Minne CE, Goudsmit J, van Oers JM, Kostense S, Havenga MJ, Osanto S, Griffioen M. Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber. Cancer Gene Ther. 2004 Mar, 11(3):227-36. (PMID: 14726960) | ||||
| LAGE-1 | 1 |
|
DR3 | 21 | QGAMLAAQERRVPRAAEVPR | ORF2 | protein | Slager, 2004 |
Slager EH, van der Minne CE, Krüse M, Krueger DD, Griffioen M, Osanto S. Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes. J Immunol. 2004 Apr 15, 172(8):5095-102. (PMID: 15067093) | ||||
| LAGE-1 | 1 |
|
DR3 | 21 | QGAMLAAQERRVPRAAEVPR | (14-33) | protein | Slager, 2004 |
Slager EH, van der Minne CE, Krüse M, Krueger DD, Griffioen M, Osanto S. Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes. J Immunol. 2004 Apr 15, 172(8):5095-102. (PMID: 15067093) | ||||
| LAGE-1 | 1 |
|
DR12 | 5 | CLSRRPWKRSWSAGSCPGMPHL | (81-102) | peptide | Slager, 2003 |
Slager EH, Borghi M, van der Minne CE, Aarnoudse CA, Havenga MJ, Schrier PI, Osanto S, Griffioen M. CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame. J Immunol. 2003 Feb 1, 170(3):1490-7. (PMID: 12538712) | ||||
| LAGE-1 | 1 |
|
DR13 | 19 | ILSRDAAPLPRPG | 108-120 | autologous tumor cells | Wang, 2004 |
Wang HY, Lee DA, Peng G, Guo Z, Li Y, Kiniwa Y, Shevach EM, Wang RF. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity. 2004 Jan, 20(1):107-18. (PMID: 14738769) | ||||
| LAGE-1 | 1 |
|
DR11 | 25 | CLSRRPWKRSWSAGSCPGMPHL | ORF2 | peptide | Slager, 2003 |
Slager EH, Borghi M, van der Minne CE, Aarnoudse CA, Havenga MJ, Schrier PI, Osanto S, Griffioen M. CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame. J Immunol. 2003 Feb 1, 170(3):1490-7. (PMID: 12538712) | ||||
| LAGE-1 | 1 |
|
DR15 | 20 | AGATGGRGPRGAGA | 37-50 | protein | Hasegawa, 2006 |
Hasegawa K, Noguchi Y, Koizumi F, Uenaka A, Tanaka M, Shimono M, Nakamura H, Shiku H, Gnjatic S, Murphy R, Hiramatsu Y, Old LJ, Nakayama E. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope. Clin Cancer Res. 2006 Mar 15, 12(6):1921-7. (PMID: 16551878) | ||||
| LAGE-1 | 1 |
|
DR11 | 25 | CLSRRPWKRSWSAGSCPGMPHL | (81-102) | peptide | Slager, 2003 |
Slager EH, Borghi M, van der Minne CE, Aarnoudse CA, Havenga MJ, Schrier PI, Osanto S, Griffioen M. CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame. J Immunol. 2003 Feb 1, 170(3):1490-7. (PMID: 12538712) | ||||
| LY6K | 1 |
|
A24 | 20 | RYCNLEGPPI | 119-128 | peptide | Suda, 2007 |
Suda T, Tsunoda T, Daigo Y, Nakamura Y, Tahara H. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci. 2007 Nov, 98(11), 1803-8. (PMID: 17784873) | ||||
| LY6K | 1 |
|
DR15 | 20 | KCCKIRYCNLEGPPINSSVF | 114-133 | peptide | Tomita, 2014 |
Tomita Y, Yuno A, Tsukamoto H, Senju S, Kuroda Y, Hirayama M, Imamura Y, Yatsuda J, Sayem MA, Irie A, Hamada A, Jono H, Yoshida K, Tsunoda T, Daigo Y, Kohrogi H, Yoshitake Y, Nakamura Y, Shinohara M, Nishimura Y. Identification of immunogenic LY6K long peptide encompassing both CD4+ and CD8+ T-cell epitopes and eliciting CD4+ T-cell immunity in patients with malignant disease. Oncoimmunology. 2014 Mar 27, e28100. (PMID: 25340007) | ||||
| LY6K | 1 |
|
DP5 | 3 | KWTEPYCVIAAVKIFPRFFMVAKQ | 61-84 | peptide | Tomita, 2014 |
Tomita Y, Yuno A, Tsukamoto H, Senju S, Kuroda Y, Hirayama M, Imamura Y, Yatsuda J, Sayem MA, Irie A, Hamada A, Jono H, Yoshida K, Tsunoda T, Daigo Y, Kohrogi H, Yoshitake Y, Nakamura Y, Shinohara M, Nishimura Y. Identification of immunogenic LY6K long peptide encompassing both CD4+ and CD8+ T-cell epitopes and eliciting CD4+ T-cell immunity in patients with malignant disease. Oncoimmunology. 2014 Mar 27, e28100. (PMID: 25340007) | ||||
| MAGE-A1 | 1 |
|
A1 | 26 | EADPTGHSY | 161-169 | autologous tumor cells | Traversari, 1992 |
Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med. 1992 Nov 1, 176(5):1453-7. (PMID: 1402688) | ||||
| MAGE-A1 | 1 |
|
A2 | 44 | KVLEYVIKV | 278-286 | peptide | Pascolo, 2001 |
Pascolo S, Schirle M, Gückel B, Dumrese T, Stumm S, Kayser S, Moris A, Wallwiener D, Rammensee HG, Stevanovic S. A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry. Cancer Res. 2001 May 15, 61(10):4072-7. (PMID: 11358828) | ||||
| MAGE-A1 | 1 |
|
A3 | 22 | SLFRAVITK | 96-104 | poxvirus-dendritic cells | Chaux, 1999 |
ALVAC recombinant proxvirus carrying the entire gene were used to infect dentritic cells. | ||||
| MAGE-A1 | 1 |
|
A2 | 44 | KVLEYVIKV | 278-286 | peptide | Ottaviani, 2005 |
Ottaviani S, Zhang Y, Boon T, van der Bruggen P. A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells. Cancer Immunol Immunother. 2005 Dec, 54(12):1214-20. (PMID: 16025263) | ||||
| LAGE-1 | 1 |
|
DR4 | 24 | AADHRQLQLSISSCLQQL | 139-156 | protein | Jäger, 2000 |
Jäger E, Jäger D, Karbach J, Chen YT, Ritter G, Nagata Y, Gnjatic S, Stockert E, Arand M, Old LJ, Knuth A. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med. 2000 Feb 21, 191(4):625-30. (PMID: 10684854) | ||||
| LAGE-1 | 1 |
|
DP4 | 75 | SLLMWITQCFLPVF | 157-170 | peptide | Zeng, 2001 |
Zeng G, Wang X, Robbins PF, Rosenberg SA, Wang RF. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci U S A. 2001 Mar 27, 98(7):3964-9. (PMID: 11259659) | ||||
| LAGE-1 | 1 |
|
DR12 | 5 | CLSRRPWKRSWSAGSCPGMPHL | ORF2 | peptide | Slager, 2003 |
Slager EH, Borghi M, van der Minne CE, Aarnoudse CA, Havenga MJ, Schrier PI, Osanto S, Griffioen M. CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame. J Immunol. 2003 Feb 1, 170(3):1490-7. (PMID: 12538712) | ||||
| MAGE-A1 | 1 |
|
A68 | 8 | EVYDGREHSA | 222-231 | poxvirus-dendritic cells | Chaux, 1999 |
Chaux P, Luiten R, Demotte N, Vantomme V, Stroobant V, Traversari C, Russo V, Schultz E, Cornelis GR, Boon T, van der Bruggen P. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J Immunol. 1999 Sep 1, 163(5):2928-36. | ||||
| MAGE-A1 | 1 |
|
B7 | 17 | RVRFFFPSL | 289-298 | poxvirus-dendritic cells | Luiten, 2000 |
Luiten R, van der Bruggen P. A MAGE-A1 peptide is recognized on HLA-B7 human tumors by cytolytic T lymphocytes. Tissue Antigens. 2000 Feb, 55(2):149-52. (PMID: 10746786) | ||||
| MAGE-A1 | 1 |
|
B35 | 20 | EADPTGHSY | 161-169 | poxvirus-dendritic cells | Luiten, 2000 |
Luiten RM, Demotte N, Tine J, van der Bruggen P. A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules. Tissue Antigens. 2000 Jul, 56(1):77-81. (PMID: 10958359) | ||||
| MAGE-A1 | 1 |
|
B37 | 3 | REPVTKAEML | 120-129 | autologous tumor cells | Tanzarella, 1999 |
Tanzarella S, Russo V, Lionello I, Dalerba P, Rigatti D, Bordignon C, Traversari C. Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family. Cancer Res. 1999 Jun 1, 59(11):2668-74. (PMID: 10363990) | ||||
| MAGE-A1 | 1 |
|
B44 | 21 | KEADPTGHSY | 160-169 | poxvirus-dendritic cells | Stroobant, 2012 |
Stroobant V, Demotte N, Luiten RM, Leonhardt RM, Cresswell P, Bonehill A, Michaux A, Ma W, Mulder A, Van den Eynde BJ, van der Bruggen P, Vigneron N. Inefficient exogenous loading of a tapasin-dependent peptide onto HLA-B*44:02 can be improved by acid treatment or fixation of target cells. Eur J Immunol. 2012 Jun, 42(6):1417-28. (PMID: 22678898) | ||||
| MAGE-A1 | 1 |
|
B53 | 2 | DPARYEFLW | 258-266 | poxvirus-dendritic cells | Chaux, 1999 |
Chaux P, Luiten R, Demotte N, Vantomme V, Stroobant V, Traversari C, Russo V, Schultz E, Cornelis GR, Boon T, van der Bruggen P. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J Immunol. 1999 Sep 1, 163(5):2928-36. (PMID: 10453041) | ||||
| MAGE-A1 | 1 |
|
B57 | 8 | ITKKVADLVGF | 102-112 | ALVAC-dendritic cells | Corbière, 2004 |
Corbière V, Nicolay H, Russo V, Stroobant V, Brichard V, Boon T, van der Bruggen P. Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors. Tissue Antigens. 2004 May, 63(5):453-7. (PMID: 15104676) | ||||
| MAGE-A1 | 1 |
|
Cw2 | 10 | SAFPTTINF | 62-70 | poxvirus-dendritic cells | Chaux, 1999 |
Chaux P, Luiten R, Demotte N, Vantomme V, Stroobant V, Traversari C, Russo V, Schultz E, Cornelis GR, Boon T, van der Bruggen P. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J Immunol. 1999 Sep 1, 163(5):2928-36. (PMID: 10453041) | ||||
| MAGE-A1 | 1 |
|
Cw3 | 17 | SAYGEPRKL | 230-238 | poxvirus-dendritic cells | Chaux, 1999 |
Chaux P, Luiten R, Demotte N, Vantomme V, Stroobant V, Traversari C, Russo V, Schultz E, Cornelis GR, Boon T, van der Bruggen P. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J Immunol. 1999 Sep 1, 163(5):2928-36. (PMID: 10453041) | ||||
| MAGE-A1 | 1 |
|
Cw7 | 41 | RVRFFFPSL | 289-298 | peptide | Goodyear, 2011 |
Goodyear OC1, Pearce H, Pratt G, Moss P. Dominant responses with conservation of T-cell receptor usage in the CD8+ T-cell recognition of a cancer testis antigen peptide presented through HLA-Cw7 in patients with multiple myeloma. Cancer Immunol Immunother. 2011 Dec, 60(12):1751-61. (PMID: 21785964) | ||||
| MAGE-A1 | 1 |
|
DP4 | 75 | TSCILESLFRAVITK | 90-104 | peptide | Wang, 2007 |
Wang XF, Cohen WM, Castelli FA, Almunia C, Lethé B, Pouvelle-Moratille S, Munier G, Charron D, Ménez A, Zarour HM, van der Bruggen P, Busson M, Maillère B. Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family. Cancer Immunol Immunother. 2007 Jun, 56(6):807-18. (PMID: 16988823) | ||||
| MAGE-A1 | 1 |
|
Cw16 | 7 | SAYGEPRKL | 230-238 | autologous tumor cells | van der Bruggen, 1994 |
van der Bruggen P1, Szikora JP, Boël P, Wildmann C, Somville M, Sensi M, Boon T. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. Eur J Immunol. 1994 Sep, 24(9):2134-40. (PMID: 7522162) | ||||
| MAGE-A1 | 1 |
|
DR13 | 19 | FLLLKYRAREPVTKAE | 112-127 | protein | Chaux, 1999 |
Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med. 1999 Mar 1, 189(5):767-78. (PMID: 10049940) | ||||
| MAGE-A1 | 1 |
|
DP4 | 75 | PRALAETSYVKVLEY | 268-282 | peptide | Wang, 2007 |
Wang XF, Cohen WM, Castelli FA, Almunia C, Lethé B, Pouvelle-Moratille S, Munier G, Charron D, Ménez A, Zarour HM, van der Bruggen P, Busson M, Maillère B. Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family. Cancer Immunol Immunother. 2007 Jun, 56(6):807-18. (PMID: 16988823) | ||||
| MAGE-A2 | 1 |
|
A2 | 44 | YLQLVFGIEV | 157-166 | peptide | Kawashima, 1998 |
Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K, Appella E, Sette A, Celis E. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol. 1998 Jan, 59(1):1-14. (PMID: 9544234) | ||||
| MAGE-A1 | 1 |
|
DR15 | 20 | EYVIKVSARVRF | 281-292 | protein | Chaux, 2001 |
Chaux P, Lethé B, Van Snick J, Corthals J, Schultz ES, Cambiaso CL, Boon T, van der Bruggen P. A MAGE-1 peptide recognized on HLA-DR15 by CD4(+) T cells. Eur J Immunol. 2001 Jun, 31(6):1910-6. (PMID: 11433388) | ||||
| MAGE-A2 | 1 |
|
A24 | 20 | EYLQLVFGI | 156-164 | peptide | Tahara, 1999 |
Tahara K, Takesako K, Sette A, Celis E, Kitano S, Akiyoshi T. Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes. Clin Cancer Res. 1999 Aug, 5(8):2236-41. (PMID: 10473111) | ||||
| GnTV | 1 |
|
A2 | 44 | VLPDVFIRC(V) | intron | autologous tumor cells | Guilloux, 1996 |
Guilloux Y1, Lucas S, Brichard VG, Van Pel A, Viret C, De Plaen E, Brasseur F, Lethé B, Jotereau F, Boon T. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J Exp Med. 1996 Mar 1, 183(3):1173-83. (PMID: 8642259) | Aberrant transcript of N acetyl glucosaminyl transferase V (GnTV) that is found only in melanomas. | |||
| MAGE-A2 | 1 |
|
Cw7 | 41 | EGDCAPEEK | 212-220 | lentivirus-dendritic cells | Breckpot, 2004 |
Breckpot K, Heirman C, De Greef C, van der Bruggen P, Thielemans K. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses. J Immunol. 2004 Feb 15, 172(4):2232-7. (PMID: 14764691) | ||||
| MAGE-A3 | 1 |
|
A2 | 44 | KVAELVHFL | 112-120 | peptide | Kawashima, 1998 |
Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K, Appella E, Sette A, Celis E. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol. 1998 Jan, 59(1):1-14. (PMID: 9544234) | ||||
| MAGE-A3 | 1 |
|
A1 | 26 | EVDPIGHLY | 168-176 | autologous tumor cells | Gaugler, 1994 |
Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethé B, Brasseur F, Boon T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med. 1994 Mar 1, 179(3):921-30. (PMID: 8113684) | ||||
| MAGE-A3 | 1 |
|
A24 | 20 | TFPDLESEF | 97-105 | peptide | Oiso, 1999 |
Oiso M, Eura M, Katsura F, Takiguchi M, Sobao Y, Masuyama K, Nakashima M, Itoh K, Ishikawa T. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes. Int J Cancer. 1999 May 5, 81(3):387-94. (PMID: 10209953) | ||||
| MAGE-A3 | 1 |
|
B18 | 6 | MEVDPIGHLY | 167-176 | adeno-dendritic cells | Bilsborough, 2002 |
Bilsborough J, Panichelli C, Duffour MT, Warnier G, Lurquin C, Schultz ES, Thielemans K, Corthals J, Boon T, van der Bruggen P. A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18. Tissue Antigens. 2002 Jul, 60(1):16-24. (PMID: 12366779) | ||||
| MAGE-A3 | 1 |
|
B35 | 20 | EVDPIGHLY | 168-176 | poxvirus-dendritic cells | Schultz, 2001 |
Schultz ES, Zhang Y, Knowles R, Tine J, Traversari C, Boon T, van der Bruggen P. A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes. Tissue Antigens. 2001 Feb, 57(2):103-9. (PMID: 11260504) | ||||
| MAGE-A3 | 1 |
|
B37 | 3 | REPVTKAEML | 127-136 | autologous tumor cells | Tanzarella, 1999 |
Tanzarella S, Russo V, Lionello I, Dalerba P, Rigatti D, Bordignon C, Traversari C. Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family. Cancer Res. 1999 Jun 1, 59(11):2668-74. (PMID: 10363990) | ||||
| MAGE-A3 | 1 |
|
B44 | 21 | MEVDPIGHLY | 167-176 | peptide | Herman, 1996 |
Herman J, van der Bruggen P, Luescher IF, Mandruzzato S, Romero P, Thonnard J, Fleischhauer K, Boon T, Coulie PG. A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. Immunogenetics. 1996, 43(6):377-83. (PMID: 8606058) | ||||
| MAGE-A3 | 1 |
|
B40 | 6 | AELVHFLLL | 114-122 | adeno-dendritic cells | Schultz, 2002 |
Schultz ES, Chapiro J, Lurquin C, Claverol S, Burlet-Schiltz O, Warnier G, Russo V, Morel S, Lévy F, Boon T, Van den Eynde BJ, van der Bruggen P. The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome. J Exp Med. 2002 Feb 18, 195(4):391-9. (PMID: 11854353) | The processing of this peptide requires immunoproteasome. | |||
| MAGE-A3 | 1 |
|
B52 | 5 | WQYFFPVIF | 143-151 | retrovirus-dendritic cells | Russo, 2000 |
Russo V, Tanzarella S, Dalerba P, Rigatti D, Rovere P, Villa A, Bordignon C, Traversari C. Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. Proc Natl Acad Sci U S A. 2000 Feb 29, 97(5):2185-90. (PMID: 10681453) | Retrovirus carrying the entire gene were used to infect dentritic celles. | |||
| MAGE-A3 | 1 |
|
DP4 | 75 | KKLLTQHFVQENYLEY | 243-258 | protein | Schultz, 2000 |
Schultz ES, Lethé B, Cambiaso CL, Van Snick J, Chaux P, Corthals J, Heirman C, Thielemans K, Boon T, van der Bruggen P. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res. 2000 Nov 15, 60(22):6272-5. (PMID: 11103782) | ||||
| MAGE-A3 | 1 |
|
Cw7 | 41 | EGDCAPEEK | 212-220 | lentivirus-dendritic cells | Breckpot, 2004 |
Breckpot K, Heirman C, De Greef C, van der Bruggen P, Thielemans K. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses. J Immunol. 2004 Feb 15, 172(4):2232-7. (PMID: 14764691) | ||||
| MAGE-A3 | 1 |
|
DP4 | 75 | RKVAELVHFLLLKYR | 111-125 | peptide | Cesson, 2011 |
Cesson V, Rivals JP, Escher A, Piotet E, Thielemans K, Posevitz V, Dojcinovic D, Monnier P, Speiser D, Bron L, Romero P. MAGE-A3 and MAGE-A4 specific CD4(+) T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes. Cancer Immunol Immunother. 2011 Jan, 60(1):23-35. (PMID: 20857101) | ||||
| MAGE-A3 | 1 |
|
DR1 | 18 | ACYEFLWGPRALVETS | 267-282 | protein | Zhang, 2003 |
Zhang Y, Chaux P, Stroobant V, Eggermont AM, Corthals J, Maillère B, Thielemans K, Marchand M, Boon T, Van Der Bruggen P. A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein. J Immunol. 2003 Jul 1, 171(1):219-25. (PMID: 12817001) | ||||
| MAGE-A2 | 1 |
|
DR13 | 19 | LLKYRAREPVTKAE | 121-134 | protein | Chaux, 1999 |
Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med. 1999 Mar 1, 189(5):767-78. (PMID: 10049940) | ||||
| MAGE-A3 | 1 |
|
DQ6 | 63 | KKLLTQHFVQENYLEY | 243-258 | peptide | Schultz, 2004 |
Schultz ES, Schuler-Thurner B, Stroobant V, Jenne L, Berger TG, Thielemanns K, van der Bruggen P, Schuler G. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy. J Immunol. 2004 Jan 15, 172(2):1304-10. (PMID: 14707109) | ||||
| MAGE-A2 | 1 |
|
B37 | 3 | REPVTKAEML | 127-136 | autologous tumor cells | Tanzarella, 1999 |
Tanzarella S, Russo V, Lionello I, Dalerba P, Rigatti D, Bordignon C, Traversari C. Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family. Cancer Res. 1999 Jun 1, 59(11):2668-74. (PMID: 10363990) | ||||
| MAGE-A3 | 1 |
|
A2 | 44 | FLWGPRALV | 271-279 | peptide | van der Bruggen, 1994 |
van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boël P, De Smet C, Traversari C, Townsend A, Boon T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol. 1994 Dec, 24(12):3038-43. (PMID: 7805731) | Only processed by the intermediate proteasome beta5i. | |||
| MAGE-A3 | 1 |
|
A24 | 20 | VAELVHFLL | 113-121 | peptide | Miyagawa, 2006 |
Miyagawa N1, Kono K, Mimura K, Omata H, Sugai H, Fujii H. A newly identified MAGE-3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells. Oncology. 2006, 70(1):54-62. (PMID: 16446550) | ||||
| MAGE-A3 | 1 |
|
DR4 | 24 | RKVAELVHFLLLKYR | 111-125 | peptide | Cesson, 2010 |
Cesson V, Rivals JP, Escher A, Piotet E, Thielemans K, Posevitz V, Dojcinovic D, Monnier P, Speiser D, Bron L, Romero P. MAGE-A3 and MAGE-A4 specific CD4(+) T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes. Cancer Immunol Immunother. 2011 Jan, 60(1):23-35. (PMID: 20857101) | ||||
| MAGE-A3 | 1 |
|
DR4 | 24 | VIFSKASSSLQL | 149-160 | peptide | Kobayashi, 2001 |
Kobayashi H, Song Y, Hoon DS, Appella E, Celis E. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res. 2001 Jun 15, 61(12):4773-8. (PMID: 11406551) | ||||
| MAGE-A3 | 1 |
|
DR7 | 25 | VIFSKASSSLQL | 149-160 | peptide | Kobayashi, 2001 |
Kobayashi H, Song Y, Hoon DS, Appella E, Celis E. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res. 2001 Jun 15, 61(12):4773-8. (PMID: 11406551) | ||||
| MAGE-A3 | 1 |
|
DR11 | 25 | GDNQIMPKAGLLIIV | 191-205 | peptide | Consogno, 2003 |
Consogno G, Manici S, Facchinetti V, Bachi A, Hammer J, Conti-Fine BM, Rugarli C, Traversari C, Protti MP. Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. Blood. 2003 Feb 1, 101(3):1038-44. (PMID: 12393675) | ||||
| MAGE-A3 | 1 |
|
DR7 | 25 | VFGIELMEVDPIGHL | 161-175 | peptide | Cesson, 2011 |
Cesson V, Rivals JP, Escher A, Piotet E, Thielemans K, Posevitz V, Dojcinovic D, Monnier P, Speiser D, Bron L, Romero P. MAGE-A3 and MAGE-A4 specific CD4(+) T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes. Cancer Immunol Immunother. 2011 Jan, 60(1):23-35. (PMID: 20857101) | ||||
| MAGE-A3 | 1 |
|
DR11 | 25 | TSYVKVLHHMVKISG | 281-295 | protein | Manici, 1999 |
Manici S, Sturniolo T, Imro MA, Hammer J, Sinigaglia F, Noppen C, Spagnoli G, Mazzi B, Bellone M, Dellabona P, Protti MP. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med. 1999 Mar 1, 189(5):871-6. (PMID: 10049951) | ||||
| MAGE-A3 | 1 |
|
DR13 | 19 | RKVAELVHFLLLKYRA | 111-126 | protein | Chaux, 1999 |
Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med. 1999 Mar 1, 189(5):767-78. (PMID: 10049940) | ||||
| MAGE-A3 | 1 |
|
DR13 | 19 | FLLLKYRAREPVTKAE | 119-134 | protein | Chaux, 1999 |
Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med. 1999 Mar 1, 189(5):767-78. (PMID: 10049940) | ||||
| MAGE-A4 | 1 |
|
A2 | 44 | GVYDGREHTV | 230-239 | adeno-dendritic cells | Duffour, 1999 |
Duffour MT, Chaux P, Lurquin C, Cornelis G, Boon T, van der Bruggen P. A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes. Eur J Immunol. 1999 Oct, 29(10):3329-37. | ||||
| MAGE-A4 | 1 |
|
A1 | 26 | EVDPASNTY | 169-177 | peptide after tetramer sorting | Kobayashi, 2003 |
Kobayashi T, Lonchay C, Colau D, Demotte N, Boon T, van der Bruggen P. New MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A1 tumor cells. Tissue Antigens. 2003 Nov, 62(5):426-32. (PMID: 14617050) | This peptide is encoded by allele MAGE-4a, which is expressed in one third of MAGE-4 positive tumor samples. The other allele, namely MAGE-4b, encodes peptide EVDPTSNTY. | |||
| MAGE-A6 | 1 |
|
B35 | 20 | EVDPIGHVY | 168-176 | autologous tumor cells | Benlalam, 2003 |
Benlalam H, Linard B, Guilloux Y, Moreau-Aubry A, Derré L, Diez E, Dreno B, Jotereau F, Labarrière N. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes. J Immunol. 2003 Dec 1, 171(11):6283-9. (PMID: 14634146) | ||||
| MAGE-A6 | 1 |
|
Cw7 | 41 | EGDCAPEEK | 212-220 | lentivirus-dendritic cells | Breckpot, 2004 |
Breckpot K, Heirman C, De Greef C, van der Bruggen P, Thielemans K. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses. J Immunol. 2004 Feb 15, 172(4):2232-7. (PMID: 14764691) | ||||
| MAGE-A4 | 1 |
|
A24 | 20 | NYKRCFPVI | 143-151 | peptide | Ottaviani, 2006 |
Ottaviani S1, Colau D, van der Bruggen P, van der Bruggen P. A new MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A24 carcinoma cells. Cancer Immunol Immunother. 2006 Jul, 55(7):867-72. (PMID: 16151806) | ||||
| MAGE-A6 | 1 |
|
DR13 | 19 | LLKYRAREPVTKAE | 121-134 | protein | Chaux, 1999 |
Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med. 1999 Mar 1, 189(5):767-78. (PMID: 10049940) | ||||
| MAGE-A6 | 1 |
|
Cw16 | 7 | ISGGPRISY | 293-301 | autologous tumor cells | Vantomme, 2003 |
Vantomme V, Boël P, De PlaenE , Boon T, van der Bruggen P. A new tumor-specific antigenic peptide encoded by MAGE-6 is presented to cytolytic T lymphocytes by HLA-Cw16. 2003 January. | ||||
| MAGE-A6 | 1 |
|
A34 | 1 | MVKISGGPR | 290-298 | autologous tumor cells | Zorn, 1999 |
Zorn E, Hercend T. A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion. Eur J Immunol. 1999 Feb, 29(2):602-7. (PMID: 10064076) | ||||
| MAGE-A10 | 1 |
|
A2 | 44 | GLYDGMEHL | 254-262 | autologous tumor cells | Huang, 1999 |
Huang LQ, Brasseur F, Serrano A, De Plaen E, van der Bruggen P, Boon T, Van Pel A. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma. J Immunol. 1999 Jun 1, 162(11):6849-54. (PMID: 10352307) | Only processed by the intermediate proteasome beta1ibeta51. | |||
| MAGE-A6 | 1 |
|
B37 | 3 | REPVTKAEML | 127-136 | autologous tumor cells | Tanzarella, 1999 |
Tanzarella S, Russo V, Lionello I, Dalerba P, Rigatti D, Bordignon C, Traversari C. Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family. Cancer Res. 1999 Jun 1, 59(11):2668-74. (PMID: 10363990) | ||||
| MAGE-A4 | 1 |
|
A24 | 20 | NYKRCFPVI | 143-151 | peptide | Miyahara, 2005 |
Miyahara Y, Naota H, Wang L, Hiasa A, Goto M, Watanabe M, Kitano S, Okumura S, Takemitsu T, Yuta A, Majima Y, Lemonnier FA, Boon T, Shiku H. Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE. Clin Cancer Res. 2005 Aug 1, 11(15):5581-9. (PMID: 16061876) | ||||
| MAGE-A4 | 1 |
|
B37 | 3 | SESLKMIF | 156-163 | poxvirus-dendritic cells | Zhang, 2002 |
Zhang Y, Stroobant V, Russo V, Boon T, van der Bruggen P. A MAGE-A4 peptide presented by HLA-B37 is recognized on human tumors by cytolytic T lymphocytes. Tissue Antigens. 2002 Nov, 60(5):365-71. (PMID: 12492812) | ||||
| MAGE-A10 | 1 |
|
B53 | 2 | DPARYEFLW | 290-298 | poxvirus-de]ndritic cells | Chaux, 1999 |
Chaux P, Luiten R, Demotte N, Vantomme V, Stroobant V, Traversari C, Russo V, Schultz E, Cornelis GR, Boon T, van der Bruggen P. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J Immunol. 1999 Sep 1, 163(5):2928-36. (PMID: 10453041) | ||||
| MAGE-A12 m | 1 |
|
A2 | 44 | FLWGPRALV | 271-279 | peptide | van der Bruggen, 1994 |
van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boël P, De Smet C, Traversari C, Townsend A, Boon T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol. 1994 Dec, 24(12):3038-43. (PMID: 7805731) | Same peptide as MAGE-A3/A2 (aa 271-279). Incompletely spliced transcript found only in melanomas. | |||
| MAGE-A12 m | 1 |
|
Cw7 | 41 | VRIGHLYIL | 170-178 | autologous tumor cells | Heidecker, 2000 |
Heidecker L, Brasseur F, Probst-Kepper M, Guéguen M, Boon T, Van den Eynde BJ. Cytolytic T lymphocytes raised against a human bladder carcinoma recognize an antigen encoded by gene MAGE-A12. J Immunol. 2000 Jun 1, 164(11):6041-5. (PMID: 10820289) | ||||
| MAGE-A12 m | 1 |
|
Cw7 | 41 | VRIGHLYIL | 170-178 | autologous tumor cells | Panelli, 2000 |
Panelli MC, Bettinotti MP, Lally K, Ohnmacht GA, Li Y, Robbins P, Riker A, Rosenberg SA, Marincola FM. A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12. J Immunol. 2000 Apr 15, 164(8):4382-92. (PMID: 10754339) | ||||
| MAGE-A12 m | 1 |
|
DP4 | 75 | REPFTKAEMLGSVIR | 127-141 | peptide | Wang, 2007 |
Wang XF, Cohen WM, Castelli FA, Almunia C, Lethé B, Pouvelle-Moratille S, Munier G, Charron D, Ménez A, Zarour HM, van der Bruggen P, Busson M, Maillère B. Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family. Cancer Immunol Immunother. 2007 Jun, 56(6):807-18. (PMID: 16988823) | ||||
| MAGE-A12 m | 1 |
|
Cw7 | 41 | EGDCAPEEK | 212-220 | lentivirus-dendritic cells | Breckpot, 2004 |
Breckpot K, Heirman C, De Greef C, van der Bruggen P, Thielemans K. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses. J Immunol. 2004 Feb 15, 172(4):2232-7. (PMID: 14764691) | ||||
| MAGE-A12 m | 1 |
|
DR13 | 19 | AELVHFLLLKYRAR | 114-127 | protein | Chaux, 1999 |
Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med. 1999 Mar 1, 189(5):767-78. (PMID: 10049940) | ||||
| MAGE-C1 | 1 |
|
A2 | 44 | ILFGISLREV | 959-968 | peptide | Anderson, 2011 |
Anderson LD Jr, Cook DR, Yamamoto TN, Berger C, Maloney DG, Riddell SR. Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma. Cancer Immunol Immunother. 2011 Jul, 60(7):985-97. (PMID: 21461886) | ||||
| MAGE-C1 | 1 |
|
DQ6 | 63 | SSALLSIFQSSPE | 137-149 | peptide | Nuber, 2010 |
Nuber N, Curioni-Fontecedro A, Matter C, Soldini D, Tiercy JM, von Boehmer L, Moch H, Dummer R, Knuth A, van den Broek M. Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients. Proc Natl Acad Sci U S A. 2010 Aug 24, 107(34):15187-92. (PMID: 20696919) | ||||
| MAGE-C1 | 1 |
|
A2 | 44 | KVVEFLAML | 1083-1091 | peptide | Anderson, 2011 |
Anderson LD Jr, Cook DR, Yamamoto TN, Berger C, Maloney DG, Riddell SR. Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma. Cancer Immunol Immunother. 2011 Jul, 60(7):985-97. (PMID: 21461886) | ||||
| MAGE-C2 | 1 |
|
A2 | 44 | ALKDVEERV | 336-344 | autologous tumor cells | Ma, 2004 |
Ma W, Germeau C, Vigneron N, Maernoudt AS, Morel S, Boon T, Coulie PG, Van den Eynde BJ. Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2. Int J Cancer. 2004 May 1, 109(5):698-702. (PMID: 14999777) | ||||
| MAGE-C1 | 1 |
|
DR15 | 20 | VSSFFSYTL | 779-787 | peptide | Nuber, 2010 |
Nuber N, Curioni-Fontecedro A, Matter C, Soldini D, Tiercy JM, von Boehmer L, Moch H, Dummer R, Knuth A, van den Broek M. Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients. Proc Natl Acad Sci U S A. 2010 Aug 24, 107(34):15187-92. (PMID: 20696919) | ||||
| MAGE-C1 | 1 |
|
DQ6 | 63 | SFSYTLLSL | 450-458 | peptide | Nuber, 2010 |
Nuber N, Curioni-Fontecedro A, Matter C, Soldini D, Tiercy JM, von Boehmer L, Moch H, Dummer R, Knuth A, van den Broek M. Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients. Proc Natl Acad Sci U S A. 2010 Aug 24, 107(34):15187-92. (PMID: 20696919) | ||||
| MAGE-C2 | 1 |
|
B44 | 21 | SESIKKKVL | 307-315 | autologous tumor cells | Godelaine, 2007 |
Godelaine D, Carrasco J, Brasseur F, Neyns B, Thielemans K, Boon T, Van Pel A. A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44. Cancer Immunol Immunother. 2007 Jun, 56(6):753-9. (56(6):753-9.) | ||||
| MAGE-C2 | 1 |
|
A2 | 44 | LLFGLALIEV | 191-200 | autologous tumor cells | Ma, 2004 |
Ma W, Germeau C, Vigneron N, Maernoudt AS, Morel S, Boon T, Coulie PG, Van den Eynde BJ. Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2. Int J Cancer. 2004 May 1, 109(5):698-702. (PMID: 14999777) | ||||
| MAGE-C2 | 1 |
|
DR15 | 20 | SSTLYLVFSPSSFST | 43-57 | peptide | Wen, 2011 |
Wen W, Zhang L, Peng J, Chen J, Hao J, Li X, Qian X, Zeng P, Zhang Y, Yin Y. Identification of promiscuous HLA-DR-restricted CD4⁺ T-cell epitopes on the cancer-testis antigen HCA587. Cancer Sci. 2011 Aug, 102(8):1455-61. (PMID: 21595801) | ||||
| mucin | 1 |
|
0 | PDTRPAPGSTAPPAHGVTSA | transfected B cells | Jerome, 1993 |
MHC-unrestricted recognition by CTL of a repeated motif that is unmasked in tumors due to mucin underglycosylation. Mucin underglycosylation also occurs in breast duct epithelial cells during lactation, but only at the extracellular apical surface, which is not accessible to T cells. | ||||||
| MAGE-C2 | 1 |
|
B57 | 8 | ASSTLYLVF | 42-50 | autologous tumor cells | Ma, 2011 |
Ma W1, Vigneron N, Chapiro J, Stroobant V, Germeau C, Boon T, Coulie PG, Van den Eynde BJ. A MAGE-C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy. Int J Cancer. 2011 Nov 15, 129(10):2427-34. (PMID: 21207413) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
A2 | 44 | SLLMWITQC | 157-165 | autologous tumor cells | Jäger, 1998 |
Jäger E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jäger D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med. 1998 Jan 19, 187(2):265-70. (PMID: 9432985) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
A2 | 44 | SLLMWITQC | 157-165 | autologous tumor cells | Chen, 2000 |
Chen JL, Dunbar PR, Gileadi U, Jäger E, Gnjatic S, Nagata Y, Stockert E, Panicali DL, Chen YT, Knuth A, Old LJ, Cerundolo V. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol. 2000 Jul 15, 165(2):948-55. (PMID: 10878370) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
A2 | 44 | SLLMWITQC | 157-165 | autologous tumor cells | Valmori, 2000 |
Valmori D, Dutoit V, Liénard D, Rimoldi D, Pittet MJ, Champagne P, Ellefsen K, Sahin U, Speiser D, Lejeune F, Cerottini JC, Romero P. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res. 2000 Aug 15, 60(16):4499-506. (PMID: 10969798) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
A2 | 44 | MLMAQEALAFL | ORF2 | autologous tumor cells | Aarnoudse, 1999 |
Aarnoudse CA, van den Doel PB, Heemskerk B, Schrier PI. Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. Int J Cancer. 1999 Jul 30, 82(3):442-8. (PMID: 10399963) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
A2 | 44 | MLMAQEALAFL | (1-11) | autologous tumor cells | Aarnoudse, 1999 |
Aarnoudse CA, van den Doel PB, Heemskerk B, Schrier PI. Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. Int J Cancer. 1999 Jul 30, 82(3):442-8. (PMID: 10399963) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
A24 | 20 | YLAMPFATPME | 91-101 | peptide | Eikawa, 2013 |
Eikawa S, Kakimi K, Isobe M, Kuzushima K, Luescher I, Ohue Y, Ikeuchi K, Uenaka A, Nishikawa H, Udono H, Oka M, Nakayama E. Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide. Int J Cancer. 2013 Jan 15, 132(2):345-54. (PMID: 22729530) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
A31 | 5 | ASGPGGGAPR | 53-62 | autologous tumor cells | Wang, 1998 |
Wang RF, Johnston SL, Zeng G, Topalian SL, Schwartzentruber DJ, Rosenberg SA. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol. 1998 Oct 1, 161(7):3598-606. (PMID: 9759882) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
A31 | 5 | LAAQERRVPR | ORF2 | autologous tumor cells | Wang, 1998 |
Wang RF, Johnston SL, Zeng G, Topalian SL, Schwartzentruber DJ, Rosenberg SA. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol. 1998 Oct 1, 161(7):3598-606. (PMID: 9759882) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
A31 | 5 | LAAQERRVPR | (18-27) | autologous tumor cells | Wang, 1998 |
Wang RF, Johnston SL, Zeng G, Topalian SL, Schwartzentruber DJ, Rosenberg SA. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol. 1998 Oct 1, 161(7):3598-606. (PMID: 9759882) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
A68 | 8 | TVSGNILTIR | 127-136 | mRNA-transfected cells | Matsuzaki, 2008 |
Matsuzaki J, Qian F, Luescher I, Lele S, Ritter G, Shrikant PA, Gnjatic S, Old LJ, Odunsi K. Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1. Cancer Immunol Immunother. 2008 Aug, 57(8):1185-95. (PMID: 18253733) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
B7 | 17 | APRGPHGGAASGL | 60-72 | peptide | Ebert, 2009 |
Ebert LM, Liu YC, Clements CS, Robson NC, Jackson HM, Markby JL, Dimopoulos N, Tan BS, Luescher IF, Davis ID, Rossjohn J, Cebon J, Purcell AW, Chen W. A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design. Cancer Res. 2009 Feb 1, 69(3):1046-54. (PMID: 19176376) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
B35 | 20 | MPFATPMEAEL | 94-104 | peptide | Eikawa, 2013 |
Eikawa S, Kakimi K, Isobe M, Kuzushima K, Luescher I, Ohue Y, Ikeuchi K, Uenaka A, Nishikawa H, Udono H, Oka M, Nakayama E. Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide. Int J Cancer. 2013 Jan 15, 132(2):345-54. (PMID: 22729530) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
B49 | 0 | KEFTVSGNILTI | 124-135 | mRNA-transfected cells | Knights, 2009 |
Knights AJ, Nuber N, Thomson CW, de la Rosa O, Jäger E, Tiercy JM, van den Broek M, Pascolo S, Knuth A, Zippelius A. Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients. Cancer Immunol Immunother. 2009 Mar, 58(3):325-38. (PMID: 18663444) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
B52 | 5 | FATPMEAEL | 96-104 | peptide | Eikawa, 2013 |
Eikawa S, Kakimi K, Isobe M, Kuzushima K, Luescher I, Ohue Y, Ikeuchi K, Uenaka A, Nishikawa H, Udono H, Oka M, Nakayama E. Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide. Int J Cancer. 2013 Jan 15, 132(2):345-54. (PMID: 22729530) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
Cw3 | 17 | LAMPFATPM | 92-100 | adenovirus-PBMC | Gnjatic, 2000 |
Gnjatic S, Nagata Y, Jager E, Stockert E, Shankara S, Roberts BL, Mazzara GP, Lee SY, Dunbar PR, Dupont B, Cerundolo V, Ritter G, Chen YT, Knuth A, Old LJ. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc Natl Acad Sci U S A. 2000 Sep 26, 97(20):10917-22. (PMID: 11005863) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
DP4 | 75 | SLLMWITQCFLPVF | 157-170 | peptide | Zeng, 2001 |
Zeng G, Wang X, Robbins PF, Rosenberg SA, Wang RF. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci U S A. 2001 Mar 27, 98(7):3964-9. (PMID: 11259659) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
DR1 | 18 | LLEFYLAMPFATPMEAELARRSLAQ | 87-111 | peptide | Mandic, 2005 |
Mandic M, Castelli F, Janjic B, Almunia C, Andrade P, Gillet D, Brusic V, Kirkwood JM, Maillere B, Zarour HM. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J Immunol. 2005 Feb 1, 174(3):1751-9. (PMID: 15661941) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
DP4 | 75 | LLEFYLAMPFATPMEAELARRSLAQ | 87-111 | peptide | Mandic, 2005 |
Mandic M, Castelli F, Janjic B, Almunia C, Andrade P, Gillet D, Brusic V, Kirkwood JM, Maillere B, Zarour HM. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J Immunol. 2005 Feb 1, 174(3):1751-9. (PMID: 15661941) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
DR1 | 18 | EFYLAMPFATPM | 89-100 | protein | Chen, 2004 |
Chen Q, Jackson H, Parente P, Luke T, Rizkalla M, Tai TY, Zhu HC, Mifsud NA, Dimopoulos N, Masterman KA, Hopkins W, Goldie H, Maraskovsky E, Green S, Miloradovic L, McCluskey J, Old LJ, Davis ID, Cebon J, Chen W. Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci U S A. 2004 Jun 22, 101(25):9363-8. (PMID: 15197261) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
DR1 | 18 | PGVLLKEFTVSGNILTIRLTAADHR | 119-143 | peptide | Ayyoub, 2010 |
Ayyoub M1, Pignon P, Dojcinovic D, Raimbaud I, Old LJ, Luescher I, Valmori D. Assessment of vaccine-induced CD4 T cell responses to the 119-143 immunodominant region of the tumor-specific antigen NY-ESO-1 using DRB1*0101 tetramers. Clin Cancer Res. 2010 Sep 15, 16(18):4607-15. (PMID: 20670945) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
DR3 | 21 | QGAMLAAQERRVPRAAEVPR | ORF2 | protein | Slager, 2004 |
Slager EH, van der Minne CE, Krüse M, Krueger DD, Griffioen M, Osanto S. Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes. J Immunol. 2004 Apr 15, 172(8):5095-102. (PMID: 15067093) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
DR2 | 25 | RLLEFYLAMPFA | 86-97 | protein | Chen, 2004 |
Chen Q1, Jackson H, Parente P, Luke T, Rizkalla M, Tai TY, Zhu HC, Mifsud NA, Dimopoulos N, Masterman KA, Hopkins W, Goldie H, Maraskovsky E, Green S, Miloradovic L, McCluskey J, Old LJ, Davis ID, Cebon J, Chen W. Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci U S A. 2004 Jun 22, 101(25):9363-8. (PMID: 15197261) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
DR3 | 21 | QGAMLAAQERRVPRAAEVPR | (14-33) | protein | Slager, 2004 |
Slager EH, van der Minne CE, Krüse M, Krueger DD, Griffioen M, Osanto S. Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes. J Immunol. 2004 Apr 15, 172(8):5095-102. (PMID: 15067093) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
Cw6 | 18 | ARGPESRLL | 80-88 | adenovirus-PBMC | Gnjatic, 2000 |
Gnjatic S, Nagata Y, Jager E, Stockert E, Shankara S, Roberts BL, Mazzara GP, Lee SY, Dunbar PR, Dupont B, Cerundolo V, Ritter G, Chen YT, Knuth A, Old LJ. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc Natl Acad Sci U S A. 2000 Sep 26, 97(20):10917-22. (PMID: 11005863) | Only processed by the intermediate proteasome beta5i. | |||
| NY-ESO-1 / LAGE-2 | 1 |
|
C12 | 12 | FATPMEAELAR | 96-106 | peptide | Eikawa, 2013 |
Eikawa S, Kakimi K, Isobe M, Kuzushima K, Luescher I, Ohue Y, Ikeuchi K, Uenaka A, Nishikawa H, Udono H, Oka M, Nakayama E. Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide. Int J Cancer. 2013 Jan 15, 132(2):345-54. (PMID: 22729530) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
B51 | 12 | MPFATPMEA | 94-102 | adenovirus-APC | Jäger, 2002 |
Jäger D, Unkelbach M, Frei C, Bert F, Scanlan M, Jäger E, Old L, Chen Y, Knuth A. Identification of tumor-restricted antigens NY-BR-1, SCP-1, and a new cancer/testis-like antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum. 2002 January. | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
DR4 | 24 | PFATPMEAELARR | 95-107 | peptide | Mizote, 2010 |
Mizote Y, Taniguchi T, Tanaka K, Isobe M, Wada H, Saika T, Kita S, Koide Y, Uenaka A, Nakayama E. Three novel NY-ESO-1 epitopes bound to DRB1*0803, DQB1*0401 and DRB1*0901 recognized by CD4 T cells from CHP-NY-ESO-1-vaccinated patients. Vaccine. 2010 Jul 19, 28(32):5338-46. (PMID: 20665979) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
DR4 | 24 | PGVLLKEFTVSGNILTIRLT | 119-138 | peptide and protein | Jäger, 2000 |
Jäger E, Jäger D, Karbach J, Chen YT, Ritter G, Nagata Y, Gnjatic S, Stockert E, Arand M, Old LJ, Knuth A. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med. 2000 Feb 21, 191(4):625-30. (PMID: 10684854) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
DR4 | 24 | PGVLLKEFTVSGNILTIRLT | 119-138 | peptide and protein | Zarour, 2000 |
Zarour HM, Storkus WJ, Brusic V, Williams E, Kirkwood JM. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res. 2000 Sep 1, 60(17):4946-52. (PMID: 10987311) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
DR4 | 24 | VLLKEFTVSG | 121-130 | peptide | Zeng, 2000 |
Zeng G, Touloukian CE, Wang X, Restifo NP, Rosenberg SA, Wang RF. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol. 2000 Jul 15, 165(2):1153-9. (PMID: 10878395) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
DR4 | 24 | AADHRQLQLSISSCLQQL | 139-156 | protein | Jäger, 2000 |
Jäger E, Jäger D, Karbach J, Chen YT, Ritter G, Nagata Y, Gnjatic S, Stockert E, Arand M, Old LJ, Knuth A. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med. 2000 Feb 21, 191(4):625-30. (PMID: 10684854) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
DR4 | 24 | LLEFYLAMPFATPMEAELARRSLAQ | 87-111 | peptide | Mandic, 2005 |
Mandic M, Castelli F, Janjic B, Almunia C, Andrade P, Gillet D, Brusic V, Kirkwood JM, Maillere B, Zarour HM. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J Immunol. 2005 Feb 1, 174(3):1751-9. (PMID: 15661941) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
DR52b | 25 | LKEFTVSGNILTIRL | 123-137 | protein | Bioley, 2009 |
Bioley G, Dousset C, Yeh A, Dupont B, Bhardwaj N, Mears G, Old LJ, Ayyoub M, Valmori D. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire. Clin Cancer Res. 2009 Jul 1, 15(13):4467-74. (PMID: 19531622) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
DR7 | 25 | PGVLLKEFTVSGNILTIRLTAADHR | 119-143 | peptide | Zarour, 2002 |
Zarour HM, Maillere B, Brusic V, Coval K, Williams E, Pouvelle-Moratille S, Castelli F, Land S, Bennouna J, Logan T, Kirkwood JM. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res. 2002 Jan 1, 62(1):213-8. (PMID: 11782380) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
DR7 | 25 | LLEFYLAMPFATPMEAELARRSLAQ | 87-111 | peptide | Mandic, 2005 |
Mandic M, Castelli F, Janjic B, Almunia C, Andrade P, Gillet D, Brusic V, Kirkwood JM, Maillere B, Zarour HM. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J Immunol. 2005 Feb 1, 174(3):1751-9. (PMID: 15661941) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
DR8 | 4 | KEFTVSGNILT | 124-134 | peptide | Mizote, 2010 |
Mizote Y, Taniguchi T, Tanaka K, Isobe M, Wada H, Saika T, Kita S, Koide Y, Uenaka A, Nakayama E. Three novel NY-ESO-1 epitopes bound to DRB1*0803, DQB1*0401 and DRB1*0901 recognized by CD4 T cells from CHP-NY-ESO-1-vaccinated patients. Vaccine. 2010 Jul 19, 28(32):5338-46. (PMID: 20665979) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
DR9 | 3 | LLEFYLAMPFATPM | 87-100 | peptide | Mizote, 2010 |
Mizote Y, Taniguchi T, Tanaka K, Isobe M, Wada H, Saika T, Kita S, Koide Y, Uenaka A, Nakayama E. Three novel NY-ESO-1 epitopes bound to DRB1*0803, DQB1*0401 and DRB1*0901 recognized by CD4 T cells from CHP-NY-ESO-1-vaccinated patients. Vaccine. 2010 Jul 19, 28(32):5338-46. (PMID: 20665979) | ||||
| NY-ESO-1 / LAGE-2 | 1 |
|
DR15 | 20 | AGATGGRGPRGAGA | 37-50 | protein | Hasegawa, 2006 |
Hasegawa K, Noguchi Y, Koizumi F, Uenaka A, Tanaka M, Shimono M, Nakamura H, Shiku H, Gnjatic S, Murphy R, Hiramatsu Y, Old LJ, Nakayama E. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope. Clin Cancer Res. 2006 Mar 15, 12(6):1921-7. (PMID: 16551878) | ||||
| SAGE | 1 |
|
A24 | 20 | LYATVIHDI | 715-723 | peptide | Miyahara, 2005 |
Miyahara Y, Naota H, Wang L, Hiasa A, Goto M, Watanabe M, Kitano S, Okumura S, Takemitsu T, Yuta A, Majima Y, Lemonnier FA, Boon T, Shiku H. Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE. Clin Cancer Res. 2005 Aug 1, 11(15):5581-9. (PMID: 16061876) | ||||
| Sp17 | 1 |
|
A1 | 26 | ILDSSEEDK | 103-111 | protein | Chiriva-Internati, 2003 |
Chiriva-Internati M, Wang Z, Pochopien S, Salati E, Lim SH. Identification of a sperm protein 17 CTL epitope restricted by HLA-A1. Int J Cancer. 2003 Dec 10, 107(5):863-5. (PMID: 14566839) | ||||
| SSX-2 | 1 |
|
A2 | 44 | KASEKIFYV | 41-49 | autologous tumor cells | Ayyoub, 2002 |
Ayyoub M, Stevanovic S, Sahin U, Guillaume P, Servis C, Rimoldi D, Valmori D, Romero P, Cerottini JC, Rammensee HG, Pfreundschuh M, Speiser D, Lévy F. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J Immunol. 2002 Feb 15, 168(4):1717-22. (PMID: 11823502) | ||||
| SSX-2 | 1 |
|
DP1 | 14 | EKIQKAFDDIAKYFSK | 19-34 | peptide | Ayyoub, 2004 |
Ayyoub M, Hesdorffer CS, Metthez G, Stevanovic S, Ritter G, Chen YT, Old LJ, Speiser D, Cerottini JC, Valmori D. Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells. J Immunol. 2004 Jun 1 , 172(11):7206-11. (PMID: 15153546) | ||||
| SSX-2 | 1 |
|
DR1 | 18 | FGRLQGISPKI | 101-111 | peptide | Neumann, 2011 |
Neumann F, Kubuschok B, Ertan K, Schormann C, Stevanovic S, Preuss KD, Schmidt W, Pfreundschuh M. A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4⁺ and CD8⁺ T-cell as well as B-cell responses. Cancer Immunol Immunother. 2011 Sep, 60(9):1333-46. (PMID: 21630107) | ||||
| SSX-2 | 1 |
|
DR3 | 21 | WEKMKASEKIFYVYMKRK | 37-54 | peptide | Ayyoub, 2005 |
Ayyoub M, Merlo A, Hesdorffer CS, Speiser D, Rimoldi D, Cerottini JC, Ritter G, Chen YT, Old LJ, Stevanovic S, Valmori D. Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2. Clin Immunol. 2005 Jan, 114(1):70-8. (PMID: 15596411) | ||||
| SSX-2 | 1 |
|
DR4 | 24 | KIFYVYMKRKYEAMT | 45-59 | peptide] | Neumann, 2004 |
Neumann F, Wagner C, Stevanovic S, Kubuschok B, Schormann C, Mischo A, Ertan K, Schmidt W, Pfreundschuh M. Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2. Int J Cancer. 2004 Nov 20, 112(4):661-8. (PMID: 15382048) | ||||
| SSX-2 | 1 |
|
DR11 | 25 | KIFYVYMKRKYEAM | 45-58 | protein | Ayyoub, 2004 |
Ayyoub M1, Hesdorffer CS, Montes M, Merlo A, Speiser D, Rimoldi D, Cerottini JC, Ritter G, Scanlan M, Old LJ, Valmori D. An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR. J Clin Invest. 2004 Apr, 113(8):1225-33. (PMID: 15085202) | ||||
| TRP2-INT2 | 1 |
|
A68 | 8 | EVISCKLIKR | intron 2 | autologous tumor cells | Lupetti, 1998 |
Lupetti R, Pisarra P, Verrecchia A, Farina C, Nicolini G, Anichini A, Bordignon C, Sensi M, Parmiani G, Traversari C. Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage. J Exp Med. 1998 Sep 21, 188(6):1005-16. (PMID: 9743519) | Incompletely spliced transcript found only in melanomas. | |||
| CEA | 2 | gut carcinoma
|
A2 | 44 | YLSGANLNL | 605-613 | peptide | Tsang, 1995 |
Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst. 1995 Jul 5, 87(13):982-90. (PMID: 7629885) | ||||
| CEA | 2 | gut carcinoma
|
A24 | 20 | TYACFVSNL | 652-660 | peptide | Nukaya, 1999 |
Nukaya I, Yasumoto M, Iwasaki T, Ideno M, Sette A, Celis E, Takesako K, Kato I. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. Int J Cancer. 1999 Jan 5, 80(1):92-7. (PMID: 9935237) | ||||
| CEA | 2 | gut carcinoma
|
A2 | 44 | GVLVGVALI | 694-702 | peptide | Alves, 2007 |
Alves PM, Viatte S, Fagerberg T, Michielin O, Bricard G, Bouzourene H, Vuilleumier H, Kruger T, Givel JC, Lévy F, Speiser DE, Cerottini JC, Romero P. Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients. Cancer Immunol Immunother. 2007 Nov, 56(11):1795-805. (PMID: 17447064) | ||||
| CEA | 2 | gut carcinoma
|
DR7 | 25 | TYYRPGVNLSLSC | 425-437 | peptide | Crosti, 2006 |
Crosti M, Longhi R, Consogno G, Melloni G, Zannini P, Protti MP. Identification of novel subdominant epitopes on the carcinoembryonic antigen recognized by CD4+ T cells of lung cancer patients. J Immunol. 2006 Apr 15, 176(8):5093-9. (PMID: 16585607) | ||||
| CEA | 2 | gut carcinoma
|
DR4 | 24 | YSWRINGIPQQHTQV | 625-639 | peptide | Ruiz, 2004 |
Ruiz M, Kobayashi H, Lasarte JJ, Prieto J, Borrás-Cuesta F, Celis E, Sarobe P. Identification and characterization of a T-helper peptide from carcinoembryonic antigen. Clin Cancer Res. 2004 Apr 15, 10(8):2860-7. (PMID: 15102695) | ||||
| CEA | 2 | gut carcinoma
|
DR9 | 3 | YACFVSNLATGRNNS | 653-667 | peptide | Kobayashi, 2002 |
Kobayashi H, Omiya R, Ruiz M, Huarte E, Sarobe P, Lasarte JJ, Herraiz M, Sangro B, Prieto J, Borras-Cuesta F, Celis E. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. Clin Cancer Res. 2002 Oct, 8(10):3219-25. (PMID: 12374692) | ||||
| CEA | 2 | gut carcinoma
|
DR7 | 25 | EIIYPNASLLIQN | 99-111 | peptide | Crosti, 2006 |
Crosti M, Longhi R, Consogno G, Melloni G, Zannini P, Protti MP. Identification of novel subdominant epitopes on the carcinoembryonic antigen recognized by CD4+ T cells of lung cancer patients. J Immunol. 2006 Apr 15, 176(8):5093-9. (PMID: 16585607) | ||||
| CEA | 2 | gut carcinoma
|
DR11 | 25 | LWWVNNQSLPVSP | 177-189 and 355-367 | peptide | Campi, 2003 |
Campi G, Crosti M, Consogno G, Facchinetti V, Conti-Fine BM, Longhi R, Casorati G, Dellabona P, Protti MP. CD4(+) T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope. Cancer Res. 2003 Dec 1, 63(23):8481-6. (PMID: 14679013) | ||||
| CEA | 2 | gut carcinoma
|
DR13 | 19 | LWWVNNQSLPVSP | 177-189 and 355-367 | peptide | Campi, 2003 |
Campi G, Crosti M, Consogno G, Facchinetti V, Conti-Fine BM, Longhi R, Casorati G, Dellabona P, Protti MP. CD4(+) T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope. Cancer Res. 2003 Dec 1, 63(23):8481-6. (PMID: 14679013) | ||||
| CEA | 2 | gut carcinoma
|
DR14 | 6 | LWWVNNQSLPVSP | 177-189 and 355-367 | peptide | Campi, 2003 |
Campi G, Crosti M, Consogno G, Facchinetti V, Conti-Fine BM, Longhi R, Casorati G, Dellabona P, Protti MP. CD4(+) T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope. Cancer Res. 2003 Dec 1, 63(23):8481-6. (PMID: 14679013) | ||||
| CEA | 2 | gut carcinoma
|
DR3 | 21 | AYVCGIQNSVSANRS | 568-582 | peptide | Crosti, 2006 |
Crosti M, Longhi R, Consogno G, Melloni G, Zannini P, Protti MP. Identification of novel subdominant epitopes on the carcinoembryonic antigen recognized by CD4+ T cells of lung cancer patients. J Immunol. 2006 Apr 15, 176(8):5093-9. (PMID: 16585607) | ||||
| CEA | 2 | gut carcinoma
|
DR14 | 6 | EIIYPNASLLIQN | 99-111 | peptide | Crosti, 2006 |
Crosti M, Longhi R, Consogno G, Melloni G, Zannini P, Protti MP. Identification of novel subdominant epitopes on the carcinoembryonic antigen recognized by CD4+ T cells of lung cancer patients. J Immunol. 2006 Apr 15, 176(8):5093-9. (PMID: 16585607) | ||||
| CEA | 2 | gut carcinoma
|
DR14 | 6 | NSIVKSITVSASG | 666-678 | peptide | Crosti, 2006 |
Crosti M, Longhi R, Consogno G, Melloni G, Zannini P, Protti MP. Identification of novel subdominant epitopes on the carcinoembryonic antigen recognized by CD4+ T cells of lung cancer patients. J Immunol. 2006 Apr 15, 176(8):5093-9. (PMID: 16585607) | ||||
| CEA | 2 | gut carcinoma
|
A3 | 22 | HLFGYSWYK | 61-69 | peptide | Kawashima, 1999 |
Kawashima I, Tsai V, Southwood S, Takesako K, Sette A, Celis E. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res. 1999 Jan 15, 59(2):431-5. (PMID: 9927058) | ||||
| CEA | 2 | gut carcinoma
|
A24 | 20 | QYSWFVNGTF | 268-277 | peptide | Nukaya, 1999 |
Nukaya I, Yasumoto M, Iwasaki T, Ideno M, Sette A, Celis E, Takesako K, Kato I. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. Int J Cancer. 1999 Jan 5, 80(1):92-7. (PMID: 9935237) | ||||
| CEA | 2 | gut carcinoma
|
A2 | 44 | IMIGVLVGV | 691-699 | peptide | Kawashima, 1998 |
Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K, Appella E, Sette A, Celis E. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol. 1998 Jan, 59(1):1-14. (PMID: 9544234) | ||||
| CEA | 2 | gut carcinoma
|
DR4 | 24 | DTGFYTLHVIKSDLVNEEATGQFRV | 116-140 | peptide | Shen, 2004 |
Shen L1, Schroers R, Hammer J, Huang XF, Chen SY. Identification of a MHC class-II restricted epitope in carcinoembryonic antigen. Cancer Immunol Immunother. 2004 May, 53(5):391-403. (PMID: 14624313) | ||||
| mammaglobin-A | 2 | breast cancer
|
A3 | 22 | PLLENVISK | 23-31 | peptide | Jaramillo, 2002 |
Jaramillo A, Majumder K, Manna PP, Fleming TP, Doherty G, Dipersio JF, Mohanakumar T. Identification of HLA-A3-restricted CD8+ T cell epitopes derived from mammaglobin-A, a tumor-associated antigen of human breast cancer. Int J Cancer. 2002 Dec 10, 102(5):499-506. (PMID: 12432553) | ||||
| Melan-A / MART-1 | 2 | melanoma
|
A2 | 44 | ILTVILGVL | 32-40 | autologous tumor cells | Castelli, 1995 |
Castelli C, Storkus WJ, Maeurer MJ, Martin DM, Huang EC, Pramanik BN, Nagabhushan TL, Parmiani G, Lotze MT. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med. 1995 Jan 1, 181(1):363-8. (PMID: 7807017 ) | ||||
| Melan-A / MART-1 | 2 | melanoma
|
A2 | 44 | (E)AAGIGILTV | 26(27)-35 | autologous tumor cells | Kawakami, 1994 |
Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med. 1994 Jul 1, 180(1):347-52. (PMID: 7516411) | ||||
| Melan-A / MART-1 | 2 | melanoma
|
B45 | 2 | AEEAAGIGIL(T) | 24-33(34) | autologous tumor cells | Schneider, 1998 |
Schneider J, Brichard V, Boon T, Meyer zum Büschenfelde KH, Wölfel T. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1. Int J Cancer. 1998 Jan 30, 75(3):451-8. (PMID: 9455808) | ||||
| Melan-A / MART-1 | 2 | melanoma
|
Cw7 | 41 | RNGYRALMDKS | 51-61 | peptide | Larrieu, 2008 |
Larrieu P, Renaud V, Godet Y, Jotereau F, Fonteneau JF. A HLA-Cw*0701 restricted Melan-A/MART1 epitope presented by melanoma tumor cells to CD8+ tumor infiltrating lymphocytes. Cancer Immunol Immunother. 2008 May, 57(5):745-52. (PMID: 18097665) | ||||
| Melan-A / MART-1 | 2 | melanoma
|
B35 | 20 | EAAGIGILTV | 26-35 | autologous tumor cells | Benlalam, 2003 |
Benlalam H, Linard B, Guilloux Y, Moreau-Aubry A, Derré L, Diez E, Dreno B, Jotereau F, Labarrière N. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes. J Immunol. 2003 Dec 1, 171(11):6283-9. (PMID: 14634146) | ||||
| Melan-A / MART-1 | 2 | melanoma
|
DP5 | 3 | YTTAEEAAGIGILTVILGVLLLIGCWYCRR | 21-50 | peptide | Meng, 2011 |
Meng Z, Wang Y, Zhang G, Ke Y, Yan Y, Wu L, Huang Q, Zeng G, Wang Y, Ying H, Jiao S. Identification of an HLA-DPB1*0501 restricted Melan-A/MART-1 epitope recognized by CD4+ T lymphocytes: prevalence for immunotherapy in Asian populations. J Immunother. 2011 Sep, 34(7):525-34. (PMID: 21760531) | ||||
| Melan-A / MART-1 | 2 | melanoma
|
DQ6 | 63 | EEAAGIGILTVI | 25-36 | peptide | Bioley, 2006 |
Bioley G, Jandus C, Tuyaerts S, Rimoldi D, Kwok WW, Speiser DE, Tiercy JM, Thielemans K, Cerottini JC, Romero P. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. J Immunol. 2006 Nov 15, 177(10):6769-79. (PMID: 17082590) | ||||
| Melan-A / MART-1 | 2 | melanoma
|
DR1 | 18 | APPAYEKLpSAEQf | 100-111 | peptide | Depontieu, 2009 |
Depontieu FR, Qian J, Zarling AL, McMiller TL, Salay TM, Norris A, English AM, Shabanowitz J, Engelhard VH, Hunt DF, Topalian SL. Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy. Proc Natl Acad Sci U S A. 2009 Jul 21, 106(29):12073-8. (PMID: 19581576) | ||||
| Melan-A / MART-1 | 2 | melanoma
|
DR1 | 18 | AAGIGILTVILGVL | 27-40 | peptide | Bioley, 2006 |
Bioley G, Jandus C, Tuyaerts S, Rimoldi D, Kwok WW, Speiser DE, Tiercy JM, Thielemans K, Cerottini JC, Romero P. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. J Immunol. 2006 Nov 15, 177(10):6769-79. (PMID: 17082590) | ||||
| Melan-A / MART-1 | 2 | melanoma
|
DR4 | 24 | RNGYRALMDKSLHVGTQCALTRR | 51-73 | peptide | Zarour, 2000 |
Zarour HM, Kirkwood JM, Kierstead LS, Herr W, Brusic V, Slingluff CL Jr, Sidney J, Sette A, Storkus WJ. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci U S A. 2000 Jan 4, 97(1):400-5. (PMID: 10618430) | ||||
| Melan-A / MART-1 | 2 | melanoma
|
DR3 | 21 | EEAAGIGILTVI | 25-36 | peptide | Bioley, 2006 |
Bioley G, Jandus C, Tuyaerts S, Rimoldi D, Kwok WW, Speiser DE, Tiercy JM, Thielemans K, Cerottini JC, Romero P. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. J Immunol. 2006 Nov 15, 177(10):6769-79. (PMID: 17082590) | ||||
| Melan-A / MART-1 | 2 | melanoma
|
DR52 | 41 | KNCEPVVPNAPPAYEKLSAE | 91-110 | peptide | Godefroy, 2006 |
Godefroy E, Scotto L, Souleimanian NE, Ritter G, Old LJ, Jotereau F, Valmori D, Ayyoub M. Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles. Clin Immunol. 2006 Oct, 121(1):54-62. (PMID: 16814609) | ||||
| Melan-A / MART-1 | 2 | melanoma
|
DR11 | 25 | MPREDAHFIYGYPKKGHGHS | 20-Jan | peptide | Godefroy, 2006 |
Godefroy E, Scotto L, Souleimanian NE, Ritter G, Old LJ, Jotereau F, Valmori D, Ayyoub M. Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles. Clin Immunol. 2006 Oct, 121(1):54-62. (PMID: 16814609) | ||||
| OA1 | 2 | melanoma
|
A24 | 20 | LYSACFWWL | 126-134 | peptide | Touloukian, 2003 |
Touloukian CE, Leitner WW, Schnur RE, Robbins PF, Li Y, Southwood S, Sette A, Rosenberg SA, Restifo NP. Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1. J Immunol. 2003 Feb 1, 170(3):1579-85. (PMID: 12538723) | ||||
| PAP | 2 | prostate cancer
|
A2 | 44 | TLMSAMTNL | 112-120 | peptide | Olson, 2010 |
Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, McNeel DG. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother. 2010 Jun, 59(6):943-53. (PMID: 20140431) | ||||
| PAP | 2 | prostate cancer
|
A2 | 44 | ALDVYNGLL | 299-307 | peptide | Olson, 2010 |
Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, McNeel DG. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother. 2010 Jun, 59(6):943-53. (PMID: 20140431) | ||||
| PAP | 2 | prostate cancer
|
A2 | 44 | FLFLLFFWL | 18-26 | peptide | Olson, 2010 |
Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, McNeel DG. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother. 2010 Jun, 59(6):943-53. (PMID: 20140431) | ||||
| NY-BR-1 | 2 | breast cancer
|
A2 | 44 | SLSKILDTV | 904-912 | peptide | Wang, 2006 |
Wang W, Epler J, Salazar LG, Riddell SR. Recognition of breast cancer cells by CD8+ cytotoxic T-cell clones specific for NY-BR-1. Cancer Res. 2006 Jul 1, 66(13):6826-33. (PMID: 16818660) | ||||
| PSA | 2 | prostate carcinoma
|
A2 | 44 | FLTPKKLQCV | 165-174 | peptide | Correale, 1997 |
Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst. 1997 Feb 19, 89(4):293-300. (PMID: 9048833) | ||||
| PSA | 2 | prostate carcinoma
|
A2 | 44 | VISNDVCAQV | 178-187 | peptide | Correale, 1997 |
Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst. 1997 Feb 19, 89(4):293-300. (PMID: 9048833) | ||||
| TRP-1 / gp75 | 2 | melanoma
|
A31 | 5 | MSLQRQFLR | alt. ORF | autologous tumor cells | Wang, 1996 |
Wang RF, Parkhurst MR, Kawakami Y, Robbins PF, Rosenberg SA. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J Exp Med. 1996 Mar 1, 183(3):1131-40. (PMID: 8642255) | ||||
| RAB38 / NY-MEL-1 | 2 | melanoma
|
A2 | 44 | VLHWDPETV | 50-58 | peptide | Walton, 2006 |
Walton SM, Gerlinger M, de la Rosa O, Nuber N, Knights A, Gati A, Laumer M, Strauss L, Exner C, Schäfer N, Urosevic M, Dummer R, Tiercy JM, Mackensen A, Jaeger E, Lévy F, Knuth A, Jäger D, Zippelius A. Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patients. J Immunol. 2006 Dec 1, 177(11):8212-8. (PMID: 17114498) | ||||
| TRP-1 / gp75 | 2 | melanoma
|
DR4 | 24 | ISPNSVFSQWRVVCDSLEDYD | 277-297 | peptide | Touloukian, 2002 |
Touloukian CE, Leitner WW, Robbins PF, Li YF, Kang X, Lapointe R, Hwu P, Rosenberg SA, Restifo NP. Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function. Cancer Res. 2002 Sep 15, 62(18):5144-7. (PMID: 12234976) | ||||
| TRP-1 / gp75 | 2 | melanoma
|
DR15 | 20 | SLPYWNFATG | 245-254 | autologous tumor cells | Robbins, 2002 |
Robbins PF, El-Gamil M, Li YF, Zeng G, Dudley M, Rosenberg SA. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma. J Immunol. 2002 Nov 15, 169(10):6036-47. (PMID: 12421991) | ||||
| TRP-2 | 2 | melanoma
|
A2 | 44 | SVYDFFVWL | 180-188 | peptide | Parkhurst, 1998 |
Parkhurst MR, Fitzgerald EB, Southwood S, Sette A, Rosenberg SA, Kawakami Y. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res. 1998 Nov 1, 58(21):4895-901. (PMID: 9809996) | ||||
| TRP-2 | 2 | melanoma
|
A2 | 44 | TLDSQVMSL | 360-368 | peptide | Noppen, 2000 |
Noppen C, Lévy F, Burri L, Zajac P, Remmel E, Schaefer C, Lüscher U, Heberer M, Spagnoli GC. Naturally processed and concealed HLA-A2.1-restricted epitopes from tumor-associated antigen tyrosinase-related protein-2. Int J Cancer. 2000 Jul 15, 87(2):241-6. (PMID: 10861482) | ||||
| TRP-2 | 2 | melanoma
|
A31 | 5 | LLGPGRPYR | 197-205 | autologous tumor cells | Wang, 1996 |
Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med. 1996 Dec 1, 184(6):2207-16. (PMID: 8976176) | ||||
| TRP-1 / gp75 | 2 | melanoma
|
DR17 | 21 | SQWRVVCDSLEDYDT | 284-298 | peptide | Osen, 2010 |
Osen W, Soltek S, Song M, Leuchs B, Steitz J, Tüting T, Eichmüller SB, Nguyen XD, Schadendorf D, Paschen A. Screening of human tumor antigens for CD4 T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries. PLoS One. 2010 Nov 30, 5(11):e14137 (PMID: 21152437) | ||||
| TRP-2 | 2 | melanoma
|
A31 | 5 | LLGPGRPYR | 197-205 | autologous tumor cells | Wang, 1998 |
Wang RF, Johnston SL, Southwood S, Sette A, Rosenberg SA. Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. J Immunol. 1998 Jan 15, 160(2):890-7. (PMID: 9551926) | ||||
| TRP-2 | 2 | melanoma
|
Cw8 | 7 | ANDPIFVVL | 387-395 | autologous tumor cells | Castelli, 1999 |
Castelli C, Tarsini P, Mazzocchi A, Rini F, Rivoltini L, Ravagnani F, Gallino F, Belli F, Parmiani G. Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens. J Immunol. 1999 Feb 1, 162(3):1739-48. (PMID: 9973437) | ||||
| TRP-2 | 2 | melanoma
|
A33 | 5 | LLGPGRPYR | 197-205 | autologous tumor cells | Wang, 1998 |
Wang RF, Johnston SL, Southwood S, Sette A, Rosenberg SA. Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. J Immunol. 1998 Jan 15, 160(2):890-7. (PMID: 9551926) | ||||
| TRP-2 | 2 | melanoma
|
DR3 | 21 | QCTEVRADTRPWSGP | 60-74 | peptide | Paschen, 2005 |
Paschen A, Song M, Osen W, Nguyen XD, Mueller-Berghaus J, Fink D, Daniel N, Donzeau M, Nagel W, Kropshofer H, Schadendorf D. Detection of spontaneous CD4+ T-cell responses in melanoma patients against a tyrosinase-related protein-2-derived epitope identified in HLA-DRB1*0301 transgenic mice. Clin Cancer Res. 2005 Jul 15, 11(14):5241-7. (PMID: 16033842) | ||||
| TRP-2 | 2 | melanoma
|
DR15 | 20 | ALPYWNFATG | 241-250 | autologous tumor cells | Robbins, 2002 |
Robbins PF, El-Gamil M, Li YF, Zeng G, Dudley M, Rosenberg SA. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma. J Immunol. 2002 Nov 15, 169(10):6036-47. (PMID: 12421991) | ||||
| tyrosinase | 2 | melanoma
|
A1 | 26 | KCDICTDEY | 243-251 | autologous tumor cells | Kittlesen, 1998 |
Kittlesen DJ, Thompson LW, Gulden PH, Skipper JC, Colella TA, Shabanowitz J, Hunt DF, Engelhard VH, Slingluff CL Jr. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development. J Immunol. 1998 Mar 1, 160(5):2099-106. (PMID: 9498746) | ||||
| tyrosinase | 2 | melanoma
|
A1 | 26 | SSDYVIPIGTY | 146-156 | autologous tumor cells | Kawakami, 1998 |
Kawakami Y, Robbins PF, Wang X, Tupesis JP, Parkhurst MR, Kang X, Sakaguchi K, Appella E, Rosenberg SA. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J Immunol. 1998 Dec 15, 161(12):6985-92. (PMID: 9862734) | ||||
| tyrosinase | 2 | melanoma
|
A2 | 44 | MLLAVLYCL | 1-9 | autologous tumor cells | Wölfel, 1994 |
Wölfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Büschenfelde KH, Boon T. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol. 1994 Mar, 24(3):759-64. (PMID: 8125142) | ||||
| tyrosinase | 2 | melanoma
|
A2 | 44 | CLLWSFQTSA | 8-17 | peptide | Riley, 2001 |
Riley JP, Rosenberg SA, Parkhurst MR. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase. J Immunother. 2001 May-Jun, 24(3):212-20. (PMID: 11394498) | ||||
| tyrosinase | 2 | melanoma
|
A2 | 44 | YMDGTMSQV | 369-377 | autologous tumor cells | Wölfel, 1994 |
Wölfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Büschenfelde KH, Boon T. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol. 1994 Mar, 24(3):759-64. (PMID: 8125142) | ||||
| tyrosinase | 2 | melanoma
|
A2 | 44 | YMDGTMSQV | 369-377 | autologous tumor cells | Skipper, 1996 |
Skipper JC, Hendrickson RC, Gulden PH, Brichard V, Van Pel A, Chen Y, Shabanowitz J, Wolfel T, Slingluff CL Jr, Boon T, Hunt DF, Engelhard VH. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med. 1996 Feb 1, 183(2):527-34. (PMID: 8627164) | ||||
| tyrosinase | 2 | melanoma
|
A24 | 20 | IYMDGTADFSF | 368-373 and 336-340e | autologous tumor cells | Dalet, 2011 |
Dalet A, Robbins PF, Stroobant V, Vigneron N, Li YF, El-Gamil M, Hanada K, Yang JC, Rosenberg SA, Van den Eynde BJ. An antigenic peptide produced by reverse splicing and double asparagine deamidation. Proc Natl Acad Sci U S A. 2011 Jul 19, 108(29):E323-31. (PMID: 21670269) | ||||
| tyrosinase | 2 | melanoma
|
A24 | 20 | AFLPWHRLF | 206-214 | autologous tumor cells | Kang, 1995 |
Kang X, Kawakami Y, el-Gamil M, Wang R, Sakaguchi K, Yannelli JR, Appella E, Rosenberg SA, Robbins PF. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J Immunol. 1995 Aug 1, 155(3):1343-8. (PMID: 7543520) | ||||
| tyrosinase | 2 | melanoma
|
A26 | 8 | QCSGNFMGF | 90-98 | autologous tumor cells | Lennerz, 2005 |
Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C, Wölfel T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A. 2005 Nov 1, 102(44):16013-8. (PMID: 16247014) | ||||
| tyrosinase | 2 | melanoma
|
B35 | 20 | LPSSADVEF | 312-320 | autologous tumor cells | Morel, 1999 |
Morel S, Ooms A, Van Pel A, Wölfel T, Brichard VG, van der Bruggen P, Van den Eynde BJ, Degiovanni G. A tyrosinase peptide presented by HLA-B35 is recognized on a human melanoma by autologous cytotoxic T lymphocytes. Int J Cancer. 1999 Dec 10, 83(6):755-9. (PMID: 10597191) | ||||
| tyrosinase | 2 | melanoma
|
B35 | 20 | TPRLPSSADVEF | 309-320 | autologous tumor cells | Benlalam, 2003 |
Benlalam H, Linard B, Guilloux Y, Moreau-Aubry A, Derré L, Diez E, Dreno B, Jotereau F, Labarrière N. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes. J Immunol. 2003 Dec 1, 171(11):6283-9. (PMID: 14634146) | ||||
| tyrosinase | 2 | melanoma
|
B38 | 5 | LHHAFVDSIF | 388-397 | autologous tumor cells | Lennerz, 2005 |
Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C, Wölfel T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A. 2005 Nov 1, 102(44):16013-8. (PMID: 16247014) | ||||
| tyrosinase | 2 | melanoma
|
DR4 | 24 | QNILLSNAPLGPQFP | 56-70 | autologous tumor cells | Topalian, 1996 |
Topalian SL, Gonzales MI, Parkhurst M, Li YF, Southwood S, Sette A, Rosenberg SA, Robbins PF. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med. 1996 May 1, 183(5):1965-71. (PMID: 8642306) | ||||
| tyrosinase | 2 | melanoma
|
DR4 | 24 | SYLQDSDPDSFQD | 450-462 | autologous tumor cells | Topalian, 1996 |
Topalian SL, Gonzales MI, Parkhurst M, Li YF, Southwood S, Sette A, Rosenberg SA, Robbins PF. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med. 1996 May 1, 183(5):1965-71. (PMID: 8642306) | ||||
| tyrosinase | 2 | melanoma
|
B44 | 21 | SEIWRDIDFd | 192-200 | autologous tumor cells | Brichard, 1996 |
Brichard VG, Herman J, Van Pel A, Wildmann C, Gaugler B, Wölfel T, Boon T, Lethé B. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur J Immunol. 1996 Jan, 26(1):224-30. (PMID: 8566071) | ||||
| tyrosinase | 2 | melanoma
|
DR15 | 20 | FLLHHAFVDSIFEQWLQRHRP | 386-406 | autologous tumor cells | Kobayashi, 1998 |
Kobayashi H, Kokubo T, Sato K, Kimura S, Asano K, Takahashi H, Iizuka H, Miyokawa N, Katagiri M. CD4+ T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase. Cancer Res. 1998 Jan 15, 58(2):296-301. (PMID: 9443408) | ||||
| adipophilin | 3 | adipocytes, macrophages
|
A2 | 44 | SVASTITGV | 129-137 | peptide | Schmidt, 2004 |
Schmidt SM, Schag K, Müller MR, Weinschenk T, Appel S, Schoor O, Weck MM, Grünebach F, Kanz L, Stevanovic S, Rammensee HG, Brossart P. Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis. Cancer Res. 2004 Feb 1, 64(3):1164-70. (PMID: 14871853) | ||||
| BCLX (L) | 3 | ubiquitous (low level)
|
A2 | 44 | YLNDHLEPWI | 173-182 | peptide | Sørensen, 2007 |
Sørensen RB1, Hadrup SR, Køllgaard T, Svane IM, thor Straten P, Andersen MH. Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient. Cancer Immunol Immunother. 2007 Apr, 56(4):527-33. (PMID: 16850344) | ||||
| BING-4 | 3 | ubiquitous (low level)
|
A2 | 44 | CQWGRLWQL | ORF2 | anti-CD3 | Rosenberg, 2002 |
Rosenberg SA, Tong-On P, Li Y, Riley JP, El-Gamil M, Parkhurst MR, Robbins PF. Identification of BING-4 cancer antigen translated from an alternative open reading frame of a gene in the extended MHC class II region using lymphocytes from a patient with a durable complete regression following immunotherapy. J Immunol. 2002 Mar 1, 168(5):2402-7. (PMID: 11859131) | ||||
| CALCA | 3 | thyroid
|
A2 | 44 | VLLQAGSLHA | 16-25 | autologous tumor cells | El Hage, 2008 |
El Hage F, Stroobant V, Vergnon I, Baurain JF, Echchakir H, Lazar V, Chouaib S, Coulie PG, Mami-Chouaib F. Preprocalcitonin signal peptide generates a cytotoxic T lymphocyte-defined tumor epitope processed by a proteasome-independent pathway. Proc Natl Acad Sci U S A. 2008 Jul 22, 105(29):10119-24. (PMID: 18626012) | ||||
| ALDH1A1 | 3 | mucosa, keratinocytes
|
A2 | 44 | LLYKLADLI | 88-96 | peptide | Visus, 2007 |
Visus C, Ito D, Amoscato A, Maciejewska-Franczak M, Abdelsalem A, Dhir R, Shin DM, Donnenberg VS, Whiteside TL, DeLeo AB. Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck. Cancer Res. 2007 Nov 1, 67(21):10538-45. (PMID: 17974998) | ||||
| cyclin D1 | 3 | ubiquitous (low level)
|
DR4 | 24 | NPPSMVAAGSVVAAV | 198-212 | peptide | Dengjel, 2004 |
Dengjel J, Decker P, Schoor O, Altenberend F, Weinschenk T, Rammensee HG, Stevanovic S. Identification of a naturally processed cyclin D1 T-helper epitope by a novel combination of HLA class II targeting and differential mass spectrometry. Eur J Immunol. 2004 Dec, 34(12):3644-51. (PMID: 15495271) | ||||
| DKK1 | 3 | testis, prostate,
|
A2 | 44 | ALGGHPLLGV | 20-29 | peptide | Qian, 2007 |
Qian J, Xie J, Hong S, Yang J, Zhang L, Han X, Wang M, Zhan F, Shaughnessy JD Jr, Epstein J, Kwak LW, Yi Q. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood. 2007 Sep 1, 110(5):1587-94. (PMID: 17515399) | ||||
| DKK1 | 3 | mesenchymal stem cells
|
A2 | 44 | ALGGHPLLGV | 20-30 | peptide | Qian, 2007 |
Qian J, Xie J, Hong S, Yang J, Zhang L, Han X, Wang M, Zhan F, Shaughnessy JD Jr, Epstein J, Kwak LW, Yi Q. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood. 2007 Sep 1, 110(5):1587-94. (PMID: 17515399) | ||||
| ENAH (hMena) | 3 | breast, prostate stroma and epithelium of colon-rectum, pancreas, endometrium
|
A2 | 44 | TMNGSKSPV | 502-510 | peptide | Di Modugno, 2004 |
Di Modugno F, Bronzi G, Scanlan MJ, Del Bello D, Cascioli S, Venturo I, Botti C, Nicotra MR, Mottolese M, Natali PG, Santoni A, Jager E, Nisticò P. Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response. Int J Cancer. 2004 May 10, 109(6):909-18. (PMID: 15027125) | ||||
| EpCAM | 3 | epithelial cells
|
A24 | 20 | RYQLDPKFI | 173-181 | peptide | Tajima, 2004 |
Tajima K, Demachi A, Ito Y, Nishida K, Akatsuka Y, Tsujimura K, Kuwano H, Mitsudomi T, Takahashi T, Kuzushima K. Identification of an epitope from the epithelial cell adhesion molecule eliciting HLA-A*2402-restricted cytotoxic T-lymphocyte responses. Tissue Antigens. 2004 Dec, 64(6):650-9. (PMID: 15546337) | ||||
| EphA3 | 3 | many
|
DR11 | 25 | DVTFNIICKKCG | 356-367 | autologous tumor cells | Chiari, 2000 |
Chiari R, Hames G, Stroobant V, Texier C, Maillère B, Boon T, Coulie PG. Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. Cancer Res. 2000 Sep 1, 60(17):4855-63. (PMID: 10987298) | ||||
| EZH2 | 3 | ubiquitous (low level)
|
A2 | 44 | FMVEDETVL | 120-128 | peptide | Itoh, 2007 |
Itoh Y, Komohara Y, Komatsu N, Minami T, Saito K, Noguchi M, Itoh K, Harada M. New peptides of the polycomb group protein enhancer of zeste homolog 2 with the potential to induce cancer-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ prostate cancer patients. Oncol Rep. 2007 Nov, 18(5):1231-7. (PMID: 17914578) | ||||
| EZH2 | 3 | ubiquitous (low level)
|
A24 | 20 | KYDCFLHPF | 291-299 | peptide | Ogata, 2004 |
Ogata R, Matsueda S, Yao A, Noguchi M, Itoh K, Harada M. Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides immunogenic in HLA-A24+ prostate cancer patients. Prostate. 2004 Sep 1, 60(4):273-81. (PMID: 15264237) | ||||
| EZH2 | 3 | ubiquitous (low level)
|
A2 | 44 | FINDEIFVEL | 165-174 | peptide | Itoh, 2007 |
Itoh Y, Komohara Y, Komatsu N, Minami T, Saito K, Noguchi M, Itoh K, Harada M. New peptides of the polycomb group protein enhancer of zeste homolog 2 with the potential to induce cancer-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ prostate cancer patients. Oncol Rep. 2007 Nov, 18(5):1231-7. (PMID: 17914578) | ||||
| EZH2 | 3 | ubiquitous (low level)
|
A24 | 20 | KYVGIEREM | 735-743 | peptide | Ogata, 2004 |
Ogata R, Matsueda S, Yao A, Noguchi M, Itoh K, Harada M. Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides immunogenic in HLA-A24+ prostate cancer patients. Prostate. 2004 Sep 1, 60(4):273-81. (PMID: 15264237) | ||||
| FGF5 | 3 | brain, kidney
|
A3 | 22 | NTYASPRFKf | 172-176 and 217-220 | autologous tumor cells | Hanada, 2004 |
Hanada K, Yewdell JW, Yang JC. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature. 2004 Jan 15, 427(6971):252-6. (PMID: 14724640) | ||||
| glypican-3 | 3 | placental and multiple tissues
|
A2 | 44 | FVGEFFTDV | 144-152 | peptide | Komori, 2006 |
Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, Fukuma D, Yokomine K, Harao M, Beppu T, Matsui M, Torigoe T, Sato N, Baba H, Nishimura Y. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res. 2006 May 1, 12(9):2689-97. (PMID: 16675560) | ||||
| glypican-3 | 3 | placental and multiple tissues
|
A24 | 20 | EYILSLEEL | 298-306 | peptide | Komori, 2006 |
Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, Fukuma D, Yokomine K, Harao M, Beppu T, Matsui M, Torigoe T, Sato N, Baba H, Nishimura Y. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res. 2006 May 1, 12(9):2689-97. (PMID: 16675560) | ||||
| CPSF | 3 | ubiquitous (low level)
|
A2 | 44 | LMLQNALTTM | 1360-1369 | autologous tumor cells | Maeda, 2002 |
Maeda Y, Ito M, Harashima N, Nakatsura T, Hida N, Imai N, Sato Y, Shichijo S, Todo S, Itoh K. Cleavage and polyadenylation specificity factor (CPSF)-derived peptides can induce HLA-A2-restricted and tumor-specific CTLs in the majority of gastrointestinal cancer patients. Int J Cancer. 2002 May 20, 99(3):409-17. (PMID: 11992410) | ||||
| CD274 | 3 | multiple tissues (lung, heart, dendritic cells,?) and induced by IFN-?
|
A2 | 44 | LLNAFTVTV | 15-23 | peptide | Munir, 2012 |
Munir S, Andersen GH, Met Ö, Donia M, Frøsig TM, Larsen SK, Klausen TW, Svane IM, Andersen MH. HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. Cancer Res. 2013 Mar 15, 73(6):1764-76. (PMID: 23328583) | ||||
| HER-2 / neu | 3 | ubiquitous (low level)
|
A2 | 44 | KIFGSLAFL | 369-377 | autologous tumor cells | Fisk, 1995 |
Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med. 1995 Jun 1, 181(6):2109-17. (PMID: 7539040) | ||||
| HER-2 / neu | 3 | ubiquitous (low level)
|
A2 | 44 | IISAVVGIL | 654-662 | peptide | Brossart, 1998 |
Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L, Brugger W. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res. 1998 Feb 15, 58(4):732-6. (PMID: 9485028) | ||||
| HER-2 / neu | 3 | ubiquitous (low level)
|
A2 | 44 | ALCRWGLLL | 13-May | peptide | Kawashima, 1998 |
Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K, Appella E, Sette A, Celis E. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol. 1998 Jan, 59(1):1-14. (PMID: 9544234) | ||||
| CD45 | 3 | proliferating cells, testis, multiple tissues (low level)
|
A24 | 20 | KFLDALISL | 556-564 | peptide | Tomita, 2011 |
Tomita Y, Imai K, Senju S, Irie A, Inoue M, Hayashida Y, Shiraishi K, Mori T, Daigo Y, Tsunoda T, Ito T, Nomori H, Nakamura Y, Kohrogi H, Nishimura Y. A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells. Cancer Sci. 2011 Apr, 102(4):697-705. (PMID: 21231984) | ||||
| cyclin D1 | 3 | ubiquitous (low level)
|
A2 | 44 | LLGATCMFV | 101-109 | peptide | Kondo, 2008 |
Kondo E, Maecker B, Weihrauch MR, Wickenhauser C, Zeng W, Nadler LM, Schultze JL, von Bergwelt-Baildon MS. Cyclin D1-specific cytotoxic T lymphocytes are present in the repertoire of cancer patients: implications for cancer immunotherapy. Clin Cancer Res. 2008 Oct 15, 14(20):6574-9. (PMID: 18927298) | ||||
| CPSF | 3 | ubiquitous (low level)
|
A2 | 44 | KVHPVIWSL | 250-258 | autologous tumor cells | Maeda, 2002 |
Maeda Y, Ito M, Harashima N, Nakatsura T, Hida N, Imai N, Sato Y, Shichijo S, Todo S, Itoh K. Cleavage and polyadenylation specificity factor (CPSF)-derived peptides can induce HLA-A2-restricted and tumor-specific CTLs in the majority of gastrointestinal cancer patients. Int J Cancer. 2002 May 20, 99(3):409-17. (PMID: 11992410) | ||||
| G250 / MN / CAIX | 3 | stomach, liver, pancreas
|
A2 | 44 | HLSTAFARV | 254-262 | peptide | Vissers, 1999 |
Vissers JL, De Vries IJ, Schreurs MW, Engelen LP, Oosterwijk E, Figdor CG, Adema GJ. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res. 1999 Nov 1, 59(21):5554-9. (PMID: 10554034) | ||||
| HER-2 / neu | 3 | ubiquitous (low level)
|
A2 | 44 | ILHNGAYSL | 435-443 | peptide | Kawashima, 1998 |
Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K, Appella E, Sette A, Celis E. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol. 1998 Jan, 59(1):1-14. (PMID: 9544234) | ||||
| HER-2 / neu | 3 | ubiquitous (low level)
|
A2 | 44 | VVLGVVFGI | 665-673 | peptide | Rongcun, 1999 |
Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H, Kono K, Hising C, Petersson M, Larsson O, Lan L, Appella E, Sette A, Celis E, Kiessling R. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol. 1999 Jul 15, 163(2):1037-44. (PMID: 10395702) | ||||
| HER-2 / neu | 3 | ubiquitous (low level)
|
A2 | 44 | YMIMVKCWMI | 952-961 | peptide | Rongcun, 1999 |
Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H, Kono K, Hising C, Petersson M, Larsson O, Lan L, Appella E, Sette A, Celis E, Kiessling R. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol. 1999 Jul 15, 163(2):1037-44. (PMID: 10395702) | ||||
| HER-2 / neu | 3 | ubiquitous (low level)
|
A2 | 44 | YLVPQQGFFC | 1023-1032 | peptide | Scardino, 2001 |
Scardino A, Alves P, Gross DA, Tourdot S, Graff-Dubois S, Angevin E, Firat H, Chouaib S, Lemonnier F, Nadler LM, Cardoso AA, Kosmatopoulos K. Identification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors. Eur J Immunol. 2001 Nov, 31(11):3261-70. (PMID: 11745343) | ||||
| HER-2 / neu | 3 | ubiquitous (low level)
|
A2 | 44 | RLLQETELV | 689-697 | peptide | Rongcun, 1999 |
Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H, Kono K, Hising C, Petersson M, Larsson O, Lan L, Appella E, Sette A, Celis E, Kiessling R. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol. 1999 Jul 15, 163(2):1037-44. (PMID: 10395702) | ||||
| HER-2 / neu | 3 | ubiquitous (low level)
|
A2 | 44 | HLYQGCQVV | 48-56 | peptide | Scardino, 2001 |
Scardino A, Alves P, Gross DA, Tourdot S, Graff-Dubois S, Angevin E, Firat H, Chouaib S, Lemonnier F, Nadler LM, Cardoso AA, Kosmatopoulos K. Identification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors. Eur J Immunol. 2001 Nov, 31(11):3261-70. (PMID: 11745343) | ||||
| HER-2 / neu | 3 | ubiquitous (low level)
|
A2 | 44 | PLQPEQLQV | 391-399 | peptided | Scardino, 2002 |
Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O, Tourdot S, Chouaib S, Nadler LM, Lemonnier FA, Vonderheide RH, Cardoso AA, Kosmatopoulos K. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol. 2002 Jun 1, 168(11):5900-6. (PMID: 12023395) | ||||
| HER-2 / neu | 3 | ubiquitous (low level)
|
A2 | 44 | ALIHHNTHL | 466-474 | peptided | Scardino, 2002 |
Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O, Tourdot S, Chouaib S, Nadler LM, Lemonnier FA, Vonderheide RH, Cardoso AA, Kosmatopoulos K. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol. 2002 Jun 1, 168(11):5900-6. (PMID: 12023395) | ||||
| HER-2 / neu | 3 | ubiquitous (low level)
|
A2 | 44 | TLEEITGYL | 402-410 | peptided | Scardino, 2002 |
Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O, Tourdot S, Chouaib S, Nadler LM, Lemonnier FA, Vonderheide RH, Cardoso AA, Kosmatopoulos K. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol. 2002 Jun 1, 168(11):5900-6. (PMID: 12023395) | ||||
| HER-2 / neu | 3 | ubiquitous (low level)
|
A3 | 22 | VLRENTSPK | 754-762 | peptide | Kawashima, 1999 |
Kawashima I, Tsai V, Southwood S, Takesako K, Sette A, Celis E. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res. 1999 Jan 15, 59(2):431-5. (PMID: 9927058) | ||||
| HER-2 / neu | 3 | ubiquitous (low level)
|
A24 | 20 | TYLPTNASL | 63-71 | peptide | Okugawa, 2000 |
Okugawa T, Ikuta Y, Takahashi Y, Obata H, Tanida K, Watanabe M, Imai S, Furugen R, Nagata Y, Toyoda N, Shiku H. A novel human HER2-derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals. Eur J Immunol. 2000 Nov, 30(11):3338-46. (PMID: 11093150) | ||||
| HLA-DOB | 3 | B lymphocytes, monocytes, blood cells, adrenals, ?
|
A2 | 44 | FLLGLIFLL | 232-240 | peptide | Kang, 2013 |
Kang YJ, Zeng W, Song W, Reinhold B, Choi J, Brusic V, Yamashita T, Munshi A, Li C, Minvielle S, Anderson KC, Munshi N, Reinherz EL, Sasada T. Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOβ as a novel target for multiple myeloma. Br J Haematol. 2013 Nov, 163(3):343-51. (PMID: 24032635) | ||||
| Hepsin | 3 | kidney, liver, skin, ?
|
A2 | 44 | SLLSGDWVL | 191-199 | peptide | Guo, 2013 |
Guo J, Li G, Tang J, Cao XB, Zhou QY, Fan ZJ, Zhu B, Pan XH. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human hepsin as novel targets for prostate cancer immunotherapy. Scand J Immunol. 2013 Sep, 78(3):248-57. (PMID: 23721092) | ||||
| Hepsin | 3 | kidney, liver, skin, ?
|
A2 | 44 | GLQLGVQAV | 229-237 | peptide | Guo, 2013 |
Guo J, Li G, Tang J, Cao XB, Zhou QY, Fan ZJ, Zhu B, Pan XH. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human hepsin as novel targets for prostate cancer immunotherapy. Scand J Immunol. 2013 Sep, 78(3):248-57. (PMID: 23721092) | ||||
| Hepsin | 3 | kidney, liver, skin, ?
|
A2 | 44 | PLTEYIQPV | 268-276 | peptide | Guo, 2013 |
Guo J, Li G, Tang J, Cao XB, Zhou QY, Fan ZJ, Zhu B, Pan XH. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human hepsin as novel targets for prostate cancer immunotherapy. Scand J Immunol. 2013 Sep, 78(3):248-57. (PMID: 23721092) | ||||
| IGF2B3 | 3 | ubiquitous (low level)
|
A2 | 44 | NLSSAEVVV | 515-523 | peptide | Tomita, 2011 |
Tomita Y, Harao M, Senju S, Imai K, Hirata S, Irie A, Inoue M, Hayashida Y, Yoshimoto K, Shiraishi K, Mori T, Nomori H, Kohrogi H, Nishimura Y. Peptides derived from human insulin-like growth factor-II mRNA binding protein 3 can induce human leukocyte antigen-A2-restricted cytotoxic T lymphocytes reactive to cancer cells. Cancer Sci. 2011 Jan, 102(1):71-8. (PMID: 21087352) | ||||
| IL13Ralpha2 | 3 |
|
A2 | 44 | WLPFGFILI | 345-353 | peptide | Okano, 2002 |
Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res. 2002 Sep, 8(9):2851-5. (PMID: 12231526) | ||||
| IGF2B3 | 3 | ubiquitous (low level)
|
A3 | 44 | RLLVPTQFV | 199-207 | peptide | Tomita, 2011 |
Tomita Y, Harao M, Senju S, Imai K, Hirata S, Irie A, Inoue M, Hayashida Y, Yoshimoto K, Shiraishi K, Mori T, Nomori H, Kohrogi H, Nishimura Y. Peptides derived from human insulin-like growth factor-II mRNA binding protein 3 can induce human leukocyte antigen-A2-restricted cytotoxic T lymphocytes reactive to cancer cells. Cancer Sci. 2011 Jan, 102(1):71-8. (PMID: 21087352) | ||||
| Intestinal carboxyl esterase | 3 | liver, intestine, kidney
|
B7 | 17 | SPRWWPTCL | alt. ORF | autologous tumor cells | Ronsin, 1999 |
Ronsin C, Chung-Scott V, Poullion I, Aknouche N, Gaudin C, Triebel F. A non-AUG-defined alternative open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ. J Immunol. 1999 Jul 1, 163(1):483-90. (PMID: 10384152) | ||||
| HER-2 / neu | 3 | ubiquitous (low level)
|
A2 | 44 | PLTSIISAV | 650-658 | peptided | Scardino, 2002 |
Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O, Tourdot S, Chouaib S, Nadler LM, Lemonnier FA, Vonderheide RH, Cardoso AA, Kosmatopoulos K. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol. 2002 Jun 1, 168(11):5900-6. (PMID: 12023395) | ||||
| alpha-foetoprotein (AFP) | 3 | liver
|
A2 | 44 | GVALQTMKQ | 542-550 | adenovirus-dendritic cells | Butterfield, 1999 |
Butterfield LH, Koh A, Meng W, Vollmer CM, Ribas A, Dissette V, Lee E, Glaspy JA, McBride WH, Economou JS. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res. 1999 Jul 1, 59(13):3134-42. (PMID: 10397256) | ||||
| alpha-foetoprotein (AFP) | 3 | liver
|
DR13 | 19 | QLAVSVILRV | 364-373 | peptide | Alisa, 2005 |
Alisa A, Ives A, Pathan AA, Navarrete CV, Williams R, Bertoletti A, Behboudi S. Analysis of CD4+ T-Cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients. Clin Cancer Res. 2005 Sep 15, 11(18):6686-94. (PMID: 16166448) | ||||
| alpha-foetoprotein (AFP) | 3 | liver
|
A2 | 44 | FMNKFIYEI | 158-166 | peptide | Pichard, 2008 |
Pichard V, Royer PJ, Richou C, Cauchin E, Goebes K, Gaignerie A, Masliah C, Gournay J, Gregoire M, Ferry N. Detection, isolation, and characterization of alpha-fetoprotein-specific T cell populations and clones using MHC class I multimer magnetic sorting. J Immunother. 2008 Apr, 31(3):246-53. (PMID: 18317363) | ||||
| Kallikrein 4 | 3 | prostate and ovarian cancer cancer
|
A2 | 44 | FLGYLILGV | 11-19 | peptide | Wilkinson, 2012 |
Wilkinson R, Woods K, D'Rozario R, Prue R, Vari F, Hardy MY, Dong Y, Clements JA, Hart DN, Radford KJ. Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients. Cancer Immunol Immunother. 2012 Feb, 61(2):169-79. (PMID: 21874303) | ||||
| Kallikrein 4 | 3 | prostate and ovarian cancer cancer
|
DR4 | 24 | LLANGRMPTVLQCVN | 155-169 | peptide | Hural, 2002 |
Hural JA, Friedman RS, McNabb A, Steen SS, Henderson RA, Kalos M. Identification of naturally processed CD4 T cell epitopes from the prostate-specific antigen kallikrein 4 using peptide-based in vitro stimulation. J Immunol. 2002 Jul 1, 169(1):557-65. (PMID: 12077288) | ||||
| Kallikrein 4 | 3 | prostate and ovarian cancer cancer
|
DP4 | 75 | SVSESDTIRSISIAS | 125-139 | peptide | Hural, 2002 |
Hural JA, Friedman RS, McNabb A, Steen SS, Henderson RA, Kalos M. Identification of naturally processed CD4 T cell epitopes from the prostate-specific antigen kallikrein 4 using peptide-based in vitro stimulation. J Immunol. 2002 Jul 1, 169(1):557-65. (PMID: 12077288) | ||||
| KIF20A | 3 | ubiquitous (low level)
|
A2 | 44 | AQPDTAPLPV | 284-293 | peptide | Imai, 2011 |
Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tomita Y, Tsunoda T, Nakagawa H, Nakamura Y, Baba H, Nishimura Y. Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer. Br J Cancer. 2011 Jan 1, 104(2):300-7. (PMID: 21179034) | ||||
| Kallikrein 4 | 3 | prostate and ovarian cancer cancer
|
DR7 | 25 | RMPTVLQCVNVSVVS | 160-174 | peptide | Hural, 2002 |
Hural JA, Friedman RS, McNabb A, Steen SS, Henderson RA, Kalos M. Identification of naturally processed CD4 T cell epitopes from the prostate-specific antigen kallikrein 4 using peptide-based in vitro stimulation. J Immunol. 2002 Jul 1, 169(1):557-65. (PMID: 12077288) | ||||
| KIF20A | 3 | ubiquitous (low level)
|
A2 | 44 | LLSDDDVVV | 12-20 | peptide | Imai, 2011 |
Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tomita Y, Tsunoda T, Nakagawa H, Nakamura Y, Baba H, Nishimura Y. Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer. Br J Cancer. 2011 Jan 1, 104(2):300-7. (PMID: 21179034) | ||||
| KIF20A | 3 | ubiquitous (low level)
|
A2 | 44 | CIAEQYHTV | 809-817 | peptide | Imai, 2011 |
Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tomita Y, Tsunoda T, Nakagawa H, Nakamura Y, Baba H, Nishimura Y. Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer. Br J Cancer. 2011 Jan 1, 104(2):300-7. (PMID: 21179034) | ||||
| Lengsin | 3 | eye lens and low level in multiple tissues
|
A2 | 44 | FLPEFGISSA | 270-279 | peptide | Nakatsugawa, 2011 |
Nakatsugawa M, Horie K, Yoshikawa T, Shimomura M, Kikuchi Y, Sakemura N, Suzuki S, Nobuoka D, Hirohashi Y, Torigoe T, Harada K, Takasu H, Sato N, Nakatsura T. Identification of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from the lung carcinoma antigen, Lengsin. Int J Oncol. 2011 Oct, 39(4):1041-9. (PMID: 21687943) | ||||
| MCSP | 3 | endothelial cells, chondrocytes, smooth muscle cells
|
DR11 | 25 | VGQDVSVLFRVTGALQ | 693-708 | peptide | Erfurt, 2007 |
Erfurt C, Sun Z, Haendle I, Schuler-Thurner B, Heirman C, Thielemans K, van der Bruggen P, Schuler G, Schultz ES. Tumor-reactive CD4+ T cell responses to the melanoma-associated chondroitin sulphate proteoglycan in melanoma patients and healthy individuals in the absence of autoimmunity. J Immunol. 2007 Jun 15, 178(12):7703-9. (PMID: 17548607) | ||||
| M-CSF | 3 | liver, kidney
|
B35 | 20 | LPAVVGLSPGEQEY | alt. ORF | autologous tumor cells | Probst-Kepper, 2001 |
Probst-Kepper M, Stroobant V, Kridel R, Gaugler B, Landry C, Brasseur F, Cosyns JP, Weynand B, Boon T, Van Den Eynde BJ. An alternative open reading frame of the human macrophage colony-stimulating factor gene is independently translated and codes for an antigenic peptide of 14 amino acids recognized by tumor-infiltrating CD8 T lymphocytes. J Exp Med. 2001 May 21, 193(10):1189-98. (PMID: 11369790) | ||||
| mdm-2 | 3 | ubiquitous (brain, muscle, lung)
|
A2 | 44 | VLFYLGQY | 53-60 | tumor lysate-pulsed APCs | Asai, 2002 |
Asai T, Storkus W, Mueller-Berghaus J, Knapp W, DeLeo A, Chikamatsu K, Whiteside T. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins. 2002 January. | ||||
| IDO1 | 3 | lymph nodes, placenta, and many cell types in the course of inflammatory response
|
A2 | 44 | ALLEIASCL | 199-207 | peptide | Sørensen, 2009 |
Sørensen RB, Berge-Hansen L, Junker N, Hansen CA, Hadrup SR, Schumacher TN, Svane IM, Becker JC, thor Straten P, Andersen MH. The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. PLoS One. 2009 Sep 7, 4(9):e6910. (PMID: 19738905 ) | ||||
| Midkine | 3 | ubiquitous (low level)
|
A2 | 44 | ALLALTSAV | 13-21 | peptide | Kerzerho, 2010 |
Kerzerho J, Adotevi O, Castelli FA, Dosset M, Bernardeau K, Szely N, Lang F, Tartour E, Maillere B. The angiogenic growth factor and biomarker midkine is a tumor-shared antigen. J Immunol. 2010 Jul 1, 185(1):418-23. (PMID: 20511550) | ||||
| MMP-2 | 3 | ubiquitous
|
A2 | 44 | GLPPDVQRVh | 560-568 | autologous tumor cells | Godefroy, 2005 |
Godefroy E, Moreau-Aubry A, Diez E, Dreno B, Jotereau F, Guilloux Y. alpha v beta3-dependent cross-presentation of matrix metalloproteinase-2 by melanoma cells gives rise to a new tumor antigen. J Exp Med. 2005 Jul 4, 202(1):61-72. (PMID: 15998788) | ||||
| MMP-7 | 3 | ubiquitous (low level)
|
A3 | 22 | SLFPNSPKWTSK | 96-107 | peptide | Yokoyama, 2008 |
Yokoyama Y, Grünebach F, Schmidt SM, Heine A, Häntschel M, Stevanovic S, Rammensee HG, Brossart P. Matrilysin (MMP-7) is a novel broadly expressed tumor antigen recognized by antigen-specific T cells. Clin Cancer Res. 2008 Sep 1, 14(17):5503-11. (PMID: 18765542) | ||||
| Midkine | 3 | ubiquitous (low level)
|
DR4 | 24 | LTLLALLALTSAVAK | 9-23 | peptide | Kerzerho, 2013 |
Kerzerho J, Schneider A, Favry E, Castelli FA, Maillère B. The signal peptide of the tumor-shared antigen midkine hosts CD4+ T cell epitopes. J Biol Chem. 2013 May 10, 288(19):13370-7. (PMID: 23553629) | ||||
| MUC1 | 3 | glandular epithelia
|
A2 | 44 | STAPPVHNV | 950-958 | peptide | Brossart, 1999 |
Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, Brugger W. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood. 1999 Jun 15, 93(12):4309-17. (PMID: 10361129) | ||||
| MUC1 | 3 | glandular epithelia
|
A2 | 44 | LLLLTVLTV | 12-20 | peptide | Brossart, 1999 |
Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, Brugger W. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood. 1999 Jun 15, 93(12):4309-17. (PMID: 10361129) | ||||
| MUC1 | 3 | glandular epithelia
|
DR3 | 21 | PGSTAPPAHGVT | repeated region | peptide | Hiltbold, 1998 |
Hiltbold EM, Ciborowski P, Finn OJ. Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells. Cancer Res. 1998 Nov 15, 58(22):5066-70. (PMID: 9823312) | ||||
| PAX5 | 3 | hemopoietic system
|
A2 | 44 | TLPGYPPHV | 311-319 | peptide | Yan, 2008 |
Yan M, Himoudi N, Pule M, Sebire N, Poon E, Blair A, Williams O, Anderson J. Development of cellular immune responses against PAX5, a novel target for cancer immunotherapy. Cancer Res. 2008 Oct 1, 68(19):8058-65. (PMID: 1882956) | ||||
| p53 | 3 | ubiquitous (low level)
|
B46 | 0 | SQKTYQGSY | 99-107 | autologous tumor cells | Azuma, 2003 |
Azuma K, Shichijo S, Maeda Y, Nakatsura T, Nonaka Y, Fujii T, Koike K, Itoh K. Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site. Cancer Res. 2003 Feb 15, 63(4):854-8. (PMID: 12591737) | ||||
| p53 | 3 | ubiquitous (low level)
|
DP5 | 3 | PGTRVRAMAIYKQ | 153-165 | peptide | Fujita, 1998 |
Fujita H, Senju S, Yokomizo H, Saya H, Ogawa M, Matsushita S, Nishimura Y. Evidence that HLA class II-restricted human CD4+ T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms. Eur J Immunol. 1998 Jan, 28(1):305-16. (PMID: 9485210) | ||||
| p53 | 3 | ubiquitous (low level)
|
A2 | 44 | RMPEAAPPV | 65-73 | peptide | Barfoed, 2000 |
Barfoed AM, Petersen TR, Kirkin AF, Thor Straten P, Claesson MH, Zeuthen J. Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein. Scand J Immunol. 2000 Feb, 51(2):128-33. (PMID: 10652158) | ||||
| PBF | 3 | ovary, pancreas, spleen, liver
|
B55 | 4 | CTACRWKKACQR | 499-510 | autologous tumor cells | Tsukahara, 2004 |
Tsukahara T, Nabeta Y, Kawaguchi S, Ikeda H, Sato Y, Shimozawa K, Ida K, Asanuma H, Hirohashi Y, Torigoe T, Hiraga H, Nagoya S, Wada T, Yamashita T, Sato N. Identification of human autologous cytotoxic T-lymphocyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor. Cancer Res. 2004 Aug 1, 64(15):5442-8. (PMID: 15289353) | ||||
| PRAME | 3 | testis, ovary, endometrium, adrenals
|
A2 | 44 | VLDGLDVLL | 100-108 | peptide | Kessler, 2001 |
Kessler JH, Beekman NJ, Bres-Vloemans SA, Verdijk P, van Veelen PA, Kloosterman-Joosten AM, Vissers DC, ten Bosch GJ, Kester MG, Sijts A, Wouter Drijfhout J, Ossendorp F, Offringa R, Melief CJ. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med. 2001 Jan 1, 193(1):73-88. (PMID: 11136822) | ||||
| PRAME | 3 | testis, ovary, endometrium, adrenals
|
A2 | 44 | ALYVDSLFFL | 300-309 | peptide | Kessler, 2001 |
Kessler JH, Beekman NJ, Bres-Vloemans SA, Verdijk P, van Veelen PA, Kloosterman-Joosten AM, Vissers DC, ten Bosch GJ, Kester MG, Sijts A, Wouter Drijfhout J, Ossendorp F, Offringa R, Melief CJ. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med. 2001 Jan 1, 193(1):73-88. (PMID: 11136822) | ||||
| PRAME | 3 | testis, ovary, endometrium, adrenals
|
A2 | 44 | SLYSFPEPEA | 142-151 | peptide | Kessler, 2001 |
Kessler JH, Beekman NJ, Bres-Vloemans SA, Verdijk P, van Veelen PA, Kloosterman-Joosten AM, Vissers DC, ten Bosch GJ, Kester MG, Sijts A, Wouter Drijfhout J, Ossendorp F, Offringa R, Melief CJ. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med. 2001 Jan 1, 193(1):73-88. (PMID: 11136822) | ||||
| PRAME | 3 | testis, ovary, endometrium, adrenals
|
A2 | 44 | SLLQHLIGL | 425-433 | peptide | Kessler, 2001 |
Kessler JH, Beekman NJ, Bres-Vloemans SA, Verdijk P, van Veelen PA, Kloosterman-Joosten AM, Vissers DC, ten Bosch GJ, Kester MG, Sijts A, Wouter Drijfhout J, Ossendorp F, Offringa R, Melief CJ. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med. 2001 Jan 1, 193(1):73-88. (PMID: 11136822) | ||||
| PSMA | 3 | prostate, CNS, liver
|
A24 | 20 | NYARTEDFF | 178-186 | peptide | Horiguchi, 2002 |
Horiguchi Y, Nukaya I, Okazawa K, Kawashima I, Fikes J, Sette A, Tachibana M, Takesako K, Murai M. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes. Clin Cancer Res. 2002 Dec, 8(12):3885-92. (PMID: 12473604) | ||||
| PRAME | 3 | testis, ovary, endometrium, adrenals
|
A24 | 20 | LYVDSLFFLc | 301-309 | autologous tumor cells | Ikeda, 1997 |
Ikeda H, Lethé B, Lehmann F, van Baren N, Baurain JF, de Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 1997 Feb, 6(2):199-208. (PMID: 9047241) | ||||
| RGS5 | 3 | heart, skeletal muscle, pericytes
|
A3 | 22 | GLASFKSFLK | 74-83 | peptide | Boss, 2007 |
Boss CN, Grünebach F, Brauer K, Häntschel M, Mirakaj V, Weinschenk T, Stevanovic S, Rammensee HG, Brossart P. Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen. Clin Cancer Res. 2007 Jun 1, 13(11):3347-55. (PMID: 17545542) | ||||
| RGS5 | 3 | heart, skeletal muscle, pericytes
|
A2 | 44 | LAALPHSCL | 5-13 | peptide | Boss, 2007 |
Boss CN, Grünebach F, Brauer K, Häntschel M, Mirakaj V, Weinschenk T, Stevanovic S, Rammensee HG, Brossart P. Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen. Clin Cancer Res. 2007 Jun 1, 13(11):3347-55. (PMID: 17545542) | ||||
| p53 | 3 | ubiquitous (low level)
|
DR14 | 6 | HLIRVEGNLRVE | 193-204 | peptide | Fujita, 1998 |
Fujita H, Senju S, Yokomizo H, Saya H, Ogawa M, Matsushita S, Nishimura Y. Evidence that HLA class II-restricted human CD4+ T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms. Eur J Immunol. 1998 Jan, 28(1):305-16. (PMID: 9485210) | ||||
| RhoC | 3 | ubiquitous (low level)
|
A3 | 22 | RAGLQVRKNK | 176-185 | peptide | Wenandy, 2008 |
Wenandy L, Sørensen RB, Svane IM, Thor Straten P, Andersen MH. RhoC a new target for therapeutic vaccination against metastatic cancer. Cancer Immunol Immunother. 2008 Dec, 57(12):1871-8. (PMID: 18415097) | ||||
| p53 | 3 | ubiquitous (low level)
|
A2 | 44 | LLGRNSFEV | 264-272 | peptide | Röpke, 1996 |
Röpke M, Hald J, Guldberg P, Zeuthen J, Nørgaard L, Fugger L, Svejgaard A, Van der Burg S, Nijman HW, Melief CJ, Claesson MH. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci U S A. 1996 Dec 10, 93(25):14704-7. (PMID: 8962118) | ||||
| RU2AS | 3 | testis, kidney, bladder
|
B7 | 17 | LPRWPPPQL | antisense | autologous tumor cells | Van Den Eynde, 1999 |
Van Den Eynde BJ, Gaugler B, Probst-Kepper M, Michaux L, Devuyst O, Lorge F, Weynants P, Boon T. A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription. J Exp Med. 1999 Dec 20, 190(12):1793-800. (PMID: 10601354) | ||||
| secernin 1 | 3 | ubiquitous
|
A2 | 44 | KMDAEHPEL | 196-204 | peptide | Suda, 2006 |
Suda T, Tsunoda T, Uchida N, Watanabe T, Hasegawa S, Satoh S, Ohgi S, Furukawa Y, Nakamura Y, Tahara H. Identification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray. Cancer Sci. 2006 May, 97(5):411-9. (PMID: 16630140) | ||||
| Midkine | 3 | ubiquitous (low level)
|
A2 | 44 | AQCQETIRV | 114-122 | peptide | Kerzerho, 2010 |
Kerzerho J, Adotevi O, Castelli FA, Dosset M, Bernardeau K, Szely N, Lang F, Tartour E, Maillere B. The angiogenic growth factor and biomarker midkine is a tumor-shared antigen. J Immunol. 2010 Jul 1, 185(1):418-23. (PMID: 20511550) | ||||
| SOX10 | 3 | ubiquitous (low level)
|
A2 | 44 | AWISKPPGV | 332-340 | tumor-infiltrating lymphocytes | Khong, 2002 |
Khong HT, Rosenberg SA. The Waardenburg syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapy. Cancer Res. 2002 Jun 1, 62(11):3020-3. (PMID: 12036907) | ||||
| SOX10 | 3 | ubiquitous (low level)
|
A2 | 44 | SAWISKPPGV | 331-340 | tumor-infiltrating lymphocytes | Khong, 2002 |
Khong HT, Rosenberg SA. The Waardenburg syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapy. Cancer Res. 2002 Jun 1, 62(11):3020-3. (PMID: 12036907) | ||||
| STEAP1 | 3 | prostate
|
A2 | 44 | MIAVFLPIV | 292-300 | peptide | Rodeberg, 2005 |
Rodeberg DA, Nuss RA, Elsawa SF, Celis E. Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes. Clin Cancer Res. 2005 Jun 15, 11(12):4545-52. (PMID: 15958640) | ||||
| STEAP1 | 3 | prostate
|
A2 | 44 | HQQYFYKIPILVINK | 102-116 | peptide | Kobayashi, 2007 |
Kobayashi H, Nagato T, Sato K, Aoki N, Kimura S, Murakami M, Iizuka H, Azumi M, Kakizaki H, Tateno M, Celis E. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner. Cancer Res. 2007 Jun 1, 67(11):5498-504. (PMID: 17545632) | ||||
| survivin | 3 | ubiquitous
|
A2 | 44 | ELTLGEFLKL | 95-104 | peptide / protein | Schmitz, 2000 |
Schmitz M, Diestelkoetter P, Weigle B, Schmachtenberg F, Stevanovic S, Ockert D, Rammensee HG, Rieber EP. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res. 2000 Sep 1, 60(17):4845-9. (PMID: 10987296) | ||||
| Telomerase | 3 | testis, thymus, bone marrow, lymph nodes
|
A2 | 44 | ILAKFLHWLe | 540-548 | peptide | Vonderheide, 1999 |
Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 1999 Jun, 10(6):673-9. (PMID: 10403642) | ||||
| Telomerase | 3 | testis, thymus, bone marrow, lymph nodes
|
DR7 | 25 | RPGLLGASVLGLDDI | 672-686 | peptide | Schroers, 2002 |
Schroers R, Huang XF, Hammer J, Zhang J, Chen SY. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. Cancer Res. 2002 May 1, 62(9):2600-5. (PMID: 11980655) | ||||
| Telomerase | 3 | testis, thymus, bone marrow, lymph nodes
|
A2 | 44 | RLVDDFLLV | 865-873 | peptide | Minev, 2000 |
Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci U S A. 2000 Apr 25, 97(9):4796-801. (PMID: 10759561) | ||||
| WT1 | 3 | testis, ovary, bone marrow, spleen
|
A1 | 26 | TSEKRPFMCAY | 317-327 | peptide | Asemissen, 2006 |
Asemissen AM, Keilholz U, Tenzer S, Müller M, Walter S, Stevanovic S, Schild H, Letsch A, Thiel E, Rammensee HG, Scheibenbogen C. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1. Clin Cancer Res. 2006 Dec 15, 12(24):7476-82. (PMID: 17189421) | ||||
| WT1 | 3 | testis, ovary, bone marrow, spleen
|
A24 | 20 | CMTWNQMNL | 235-243 | peptide | Ohminami, 2000 |
Ohminami H1, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood. 2000 Jan 1, 95(1):286-93. (PMID: 10607714) | ||||
| survivin | 3 | ubiquitous
|
A2 | 44 | ELTLGEFLKL | 95-104 | peptide / protein | Schmidt, 2003 |
Schmidt SM, Schag K, Müller MR, Weck MM, Appel S, Kanz L, Grünebach F, Brossart P. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood. 2003 Jul 15, 102(2):571-6. (PMID: 12576330) | ||||
| TPBG | 3 | multiple tissues (esophagus, bladder, ?)
|
A2 | 44 | RLARLALVL | 17-25 | peptide | Tykodi, 2012 |
Tykodi SS, Satoh S, Deming JD, Chou J, Harrop R, Warren EH. CD8+ T-cell clones specific for the 5T4 antigen target renal cell carcinoma tumor-initiating cells in a murine xenograft model. J Immunother. 2012 Sep, 35(7):523-33. (PMID: 22892449) | ||||
| WT1 | 3 | testis, ovary, bone marrow, spleen
|
DP5 | 3 | KRYFKLSHLQMHSRKH | 332-347 | peptide | Lin, 2013 |
Lin Y, Fujiki F, Katsuhara A, Oka Y, Tsuboi A, Aoyama N, Tanii S, Nakajima H, Tatsumi N, Morimoto S, Tamanaka T, Tachino S, Hosen N, Nishida S, Oji Y, Kumanogoh A, Sugiyama H. HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells. J Immunother. 2013 Apr, 36(3):159-70. (PMID: 23502763) | ||||
| WT1 | 3 | testis, ovary, bone marrow, spleen
|
DR4 | 24 | KRYFKLSHLQMHSRKH | 332-347 | peptide | Fujiki, 2007 |
Fujiki F1, Oka Y, Tsuboi A, Kawakami M, Kawakatsu M, Nakajima H, Elisseeva OA, Harada Y, Ito K, Li Z, Tatsumi N, Sakaguchi N, Fujioka T, Masuda T, Yasukawa M, Udaka K, Kawase I, Oji Y, Sugiyama H. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes. J Immunother. 2007 Apr, 30(3):282-93. (PMID: 17414319) | ||||
| VEGF | 3 | ubiquitous (low level)
|
B27 | 7 | SRFGGAVVR | -i | peptide | Weinzierl, 2008 |
Weinzierl AO1, Maurer D, Altenberend F, Schneiderhan-Marra N, Klingel K, Schoor O, Wernet D, Joos T, Rammensee HG, Stevanović S. A cryptic vascular endothelial growth factor T-cell epitope: identification and characterization by mass spectrometry and T-cell assays. Cancer Res. 2008 Apr 1, 68(7):2447-54. (PMID: 18381453) | ||||
| WT1 | 3 | testis, ovary, bone marrow, spleen
|
DP5 | 3 | LSHLQMHSRKH | 337-347 | peptide | Guo, 2005 |
Guo Y, Niiya H, Azuma T, Uchida N, Yakushijin Y, Sakai I, Hato T, Takahashi M, Senju S, Nishimura Y, Yasukawa M. Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted manner. Blood. 2005 Aug 15, 106(4):1415-8. (PMID: 15845894) | ||||
| Telomerase | 3 | testis, thymus, bone marrow, lymph nodes
|
DR11 | 25 | LTDLQPYMRQFVAHL | 766-780 | peptide | Schroers, 2003 |
Schroers R, Shen L, Rollins L, Rooney CM, Slawin K, Sonderstrup G, Huang XF, Chen SY. Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res. 2003 Oct 15, 9(13):4743-55. (PMID: 14581345) | ||||
| survivin | 3 | ubiquitous
|
DR1 | 18 | TLGEFLKLDRERAKN | 97-111 | peptide / protein | Widenmeyer, 2012 |
Widenmeyer M, Griesemann H, Stevanović S, Feyerabend S, Klein R, Attig S, Hennenlotter J, Wernet D, Kuprash DV, Sazykin AY, Pascolo S, Stenzl A, Gouttefangeas C, Rammensee HG. Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients. Int J Cancer. 2012 Jul 1, 131(1):140-9. (PMID: 21858810) | ||||
| glypican-3 | 3 | placental and multiple tissues
|
A2 | 44 | TIHDSIQYV | 325-334 | mRNA-transfected cells | Dargel, 2015 |
Dargel C, Bassani-Sternberg M, Hasreiter J, Zani F, Bockmann JH, Thiele F, Bohne F, Wisskirchen K, Wilde S, Sprinzl MF, Schendel DJ, Krackhardt AM, Uckert W, Wohlleber D, Schiemann M, Stemmer K, Heikenwälder M, Busch DH, Richter G, Mann M, Protzer U. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice. Gastroenterology. 2015, 149(4): 1042-52. (PMID: 26052074) | ||||
| nectin-4 | 3 | placental tissues and salivary gland
|
A2 | 44 | VLVPPLPSL | 145-153 | peptide | Lopez, 2016 |
Lopez M, Ghidouche A, Rochas C, Godelaine D, Carrasco J, Colau D, Hames G, Montero-Julian FA, Coulie PG, Olive D. Identification of a naturally processed HLA-A*02:01-restricted CTL epitope from the human tumor-associated antigen Nectin-4. Cancer Immunol Immunother. 2016, 65(10): 1177-88. (PMID: 27514672) | ||||
| IMP-3 | 3 | ubiquitous (low level)
|
DR53 | 49 | QSETETVHLFIPALSVGAIIGK | 402-423 | peptide | Hirayama, 2016 |
Hirayama M, Tomita Y, Yuno A, Tsukamoto H, Senju S, Imamura Y, Sayem MA, Irie A, Yoshitake Y, Fukuma D, Shinohara M, Hamada A, Jono H, Yuba E, Kono K, Yoshida K, Tsunoda T, Nakayama H, Nishimura Y. An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs. Oncoimmunology. 2016, 5(6) :e1123368. (PMID: 27471607) | ||||
| IMP-3 | 3 | ubiquitous (low level)
|
DR9 | 3 | GKTVNELQNLSSAEVVVPRDQ | 507-527 | peptide | Hirayama, 2016 |
Hirayama M, Tomita Y, Yuno A, Tsukamoto H, Senju S, Imamura Y, Sayem MA, Irie A, Yoshitake Y, Fukuma D, Shinohara M, Hamada A, Jono H, Yuba E, Kono K, Yoshida K, Tsunoda T, Nakayama H, Nishimura Y. An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs. Oncoimmunology. 2016, 5(6) :e1123368. (PMID: 27471607) | ||||
| PLAC1 | 3 | testis, skeletal muscle, lung
|
A2 | 44 | VLCSIDWFM | 28-36 | peptide | Li, 2018 |
Li Q, Liu M, Wu M, Zhou X, Wang S, Hu Y, Wang Y, He Y, Zeng X, Chen J, Liu Q, Xiao D, Hu X, Liu W. PLAC1-specific TCR-engineered T cells mediate antigen-specific antitumor effects in breast cancer. Oncol Lett. 2018, 15(4): 5924-5932. (PMID: 29556312) | ||||
| HLA-G | 3 | lung, pituitary, multiple tissues (low level)
|
DR53 | 49 | SHSMRYFSAAVSRPG | 26-40 | peptide | Ishibashi, 2016 |
Ishibashi K, Kumai T, Ohkuri T, Kosaka A, Nagato T, Hirata Y, Ohara K, Oikawa K, Aoki N, Akiyama N, Sado M, Kitada M, Harabuchi Y, Celis E, Kobayashi H. Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy. Oncoimmunology. 2016, 5(6): e1169356. (PMID: 7471649) | ||||
| HLA-G | 3 | lung, pituitary, multiple tissues (low level)
|
DR15 | 20 | SHSMRYFSAAVSRPG | 26-40 | peptide | Ishibashi, 2016 |
Ishibashi K, Kumai T, Ohkuri T, Kosaka A, Nagato T, Hirata Y, Ohara K, Oikawa K, Aoki N, Akiyama N, Sado M, Kitada M, Harabuchi Y, Celis E, Kobayashi H. Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy. Oncoimmunology. 2016, 5(6): e1169356. (PMID: 7471649) | ||||
| NY-ESO-1/LAGE-2 | 1 |
|
DR7 | 25 | LLEFYLAMPFATPM | 87-99 | Costa Nunes, 2019 |
Costa-Nunes C, Cachot A, Bobisse S, Arnaud M, Genolet R, Baumgaertner P, Speiser DE, Sousa Alves PM, Sandoval F, Adotévi O, Reith W, Protti MP, Coukos G, Harari A, Romero P, Jandus C. High-throughput screening of human tumor antigen–specific CD4 T cells, including neoantigen-reactive T cells. Clin Cancer Res. 2019 Jul 15, 25(14):4320-4331. (PMID: 31015344) | |||||
| LRPAP1 | 1 |
|
A2 | 44 | FLGPWAAS | 21-30 | peptide | Marijt, 2019 |
Marijt KA, Blijleven L, Verdegaal EME, Kester MG, Kowalewski DJ, Rammensee HG, Stevanović S, Heemskerk MHM, van der Burg SH, van Hall T. Identification of non-mutated neoantigens presented by TAP-deficient tumors. J Exp Med. 2018 Sep 3, 215(9):2325-2337. (PMID: 30115740) | TAP-independent processing pathway | |||
| CT37/FMR1NB | 1 |
|
A2 | 44 | YLCSGSSYFV | 89-98 | peptide | Flores-Villanueva, 2018 |
|||||
| CALCA | 3 | thyroid
|
A2 | 44 | FLALSILVL | 9-17 | peptide | Durgeau, 2018 |
Durgeau A, Virk Y, Gros G, Voilin E, Corgnac S, Djenidi F, Salmon J, Adam J, de Montpréville V, Validire P, Ferrone S, Chouaib S, Eggermont A, Soria JC, Lemonnier F, Tartour E, Chaput N, Besse B, Mami-Chouaib F. Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. at Commun. 2018 Nov 30, 9(1):5097. (PMID: 30504837) | ||||
| CALCA | 3 | thyroid
|
A2 | 44 | LLAALVQDYL | 50-59 | peptide | Durgeau, 2018 |
Durgeau A, Virk Y, Gros G, Voilin E, Corgnac S, Djenidi F, Salmon J, Adam J, de Montpréville V, Validire P, Ferrone S, Chouaib S, Eggermont A, Soria JC, Lemonnier F, Tartour E, Chaput N, Besse B, Mami-Chouaib F. Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. at Commun. 2018 Nov 30, 9(1):5097. (PMID: 30504837) | ||||
| CALCA | 3 | thyroid
|
A2 | 44 | CMLGTYTQDF | 91-100 | peptide | Durgeau, 2018 |
Durgeau A, Virk Y, Gros G, Voilin E, Corgnac S, Djenidi F, Salmon J, Adam J, de Montpréville V, Validire P, Ferrone S, Chouaib S, Eggermont A, Soria JC, Lemonnier F, Tartour E, Chaput N, Besse B, Mami-Chouaib F. Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. at Commun. 2018 Nov 30, 9(1):5097. (PMID: 30504837) | ||||
| HEPACAM | 3 |
|
A2 | 44 | RLAPFVYLL | 16-24 | peptide | Neidert, 2018 |
Neidert MC, Kowalewski DJ, Silginer M, Kapolou K, Backert L, Freudenmann LK, Peper JK, Marcu A, Wang SS, Walz JS, Wolpert F, Rammensee HG, Henschler R, Lamszus K, Westphal M, Roth P, Regli L, Stevanović S, Weller M, Eisele G. The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy. Acta Neuropathol. 2018 Jun, 135(6):923-938. (PMID: 29557506) | ||||
|
Cyclin-A1
|
1 |
|
A2 | 44 | SLMEPPAVLLL | 410-420 | Peptide | Teck, 2020 |
Teck AT, Urban S, Quass P, Nelde A, Schuster H, Letsch A, Busse A, Walz JS, Keilholz U, Ochsenreither S. Cancer testis antigen Cyclin A1 harbors several HLA-A*02:01-restricted T cell epitopes, which are presented and recognized in vivo. Cancer Immunol Immunother. 2020 Jul 69(7):1217-1227. (PMID: 32157447 | ||||
|
Telomerase
|
3 | testis, thymus, bone marrow, lymph nodes
|
DP4 | 75 | EARPALLTSRLRFIPK | 611-626 | peptide | Bernhardt, 2006 |
Bernhardt SL, Gjertsen MK, Trachsel S, Møller M, Eriksen JA, Meo M, Buanes T, Gaudernack G. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer. 2006; 95(11):1474-82. (PMCID: PMC2360729) |
Selected reference:
Potential antigenic peptide references
Did you find an article that is not present in the database? Please let us know.
 |
© Pierre van der Bruggen  Login |